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ABSTRACT 
Evidence shows that patients receiving amiodarone therapy have not adhered to monitoring 
guidelines set forth by the Heart Rhythm Society. Uncertainty with responsibility for monitoring 
has led to the development of pharmacist-managed or multidisciplinary-managed outpatient 
amiodarone clinics. Some limitations have been identified in the pharmacist-managed outpatient 
clinics that may be overcome by advanced practice nurse (APN)-managed clinics. The purpose 
of this EBP project was to determine what effects an APN-led amiodarone clinic would have on 
adherence to amiodarone monitoring guidelines. Using the PICOT format, the clinical question 
was developed: Does enrollment in an amiodarone clinic compared with “usual care” change 
adherence to monitoring as recommended by best practice guidelines and allow for earlier 
recognition of adverse effects of amiodarone to decrease negative patient outcomes over a four 
month time period? Using King’s theory of goal attainment and the ACE Star model, guidelines 
for monitoring patients newly started on amiodarone therapy were implemented at a northwest 
Indiana cardiology practice. Following enrollment, data were collected via chart reviews and 
compared to a usual care group which consisted of patients seen in the office during the 
previous year who did not receive care based on monitoring guidelines. When the two groups 
were compared using the chi-square of independence, a significant difference was found in the 
post-amiodarone group for baseline EKG (X2 (1) = 4.56, p = .03).  Although results were not 
statistically different for baseline TFT (X2 (1) = 1.35, p = .25), LFT, (X2 (1) = 2.55, p = .11), CXR 
(X2 (1) = 3.32, p = .07), and PFT (X2 (1) = 1.55, p = .21) diagnostics, those participants in the 
post-amiodarone clinic group were more likely to complete the recommended diagnostics. This 
small-scale APN-led amiodarone clinic improved amiodarone monitoring adherence leading to 
the possibility of future practice of APN-led therapeutic drug monitoring clinics.   
Keywords: advanced practice nurse, amiodarone, cardiology, monitoring 
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CHAPTER 1 
INTRODUCTION 
 Evidence shows that patients receiving amiodarone therapy for various arrhythmias 
have not adhered to monitoring guidelines set forth by the Heart Rhythm Society (HRS), 
formerly the North American Society for Pacing and Electrophysiology (NASPE) (Goldschlager 
et al., 2007). One reason for this lack of adherence may be the providers’ uncertainty over 
responsibility for monitoring amiodarone adverse effects (Dixon, Thanavaro, Thais, & Lavin, 
2013). The literature reviewed depicts various outpatient clinics dedicated to the monitoring of 
amiodarone according to HRS guidelines (Goldschlager et al., 2007) through pharmacist-
managed practices as well as multidisciplinary practices. Some limitations have been identified 
in the pharmacist-managed outpatient clinics that may be overcome by advanced practice nurse 
(APN) managed clinics.  
Background 
Amiodarone is an effective treatment for patients with atrial and ventricular arrhythmias. 
Amiodarone is approved by the Food and Drug Administration (FDA) for the treatment of 
recurrent, hemodynamically unstable ventricular fibrillation or ventricular tachycardia especially 
in patients with structural heart disease, those with left ventricular dysfunction, and those with 
recurrent ventricular tachycardia or for the suppression/prophylaxis against atrial fibrillation with 
rapid ventricular rates (Goldschlager et al., 2007). Although amiodarone is not FDA-approved 
for the treatment of atrial fibrillation, studies have shown that amiodarone has higher rates of 
maintaining sinus rhythm at one year compared to other antiarrhythmic medications such as 
propafenone and sotalol (Goldschlager et al., 2007). However, amiodarone is not a benign 
medication. It has a half-life measured in weeks to months rather than hours and is highly lipid-
soluble (Siddoway, 2003). Its lipophilic properties cause amiodarone to be stored in the lungs, 
liver, fat, skin, and other organs. Amiodarone also has effects on the gastrointestinal system, 
central nervous system, genitourinary system, and ocular system. Absorption from the 
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gastrointestinal tract is slow; therefore, it may be months before oral amiodarone reaches its full 
therapeutic effect (Dulak, 2005). 
 Due to its potential for serious adverse effects, the HRS has issued recommendations 
for baseline testing and follow-up for those patients on chronic amiodarone therapy 
(Goldschlager et al., 2007). Issues related to follow-up include: 
 The continued assessment of drug efficacy 
 Titration of drug dose after achieving a steady state; evaluation of adverse and toxic 
effects 
 Appropriate management of toxic effects 
 Attention to important drug-drug interactions 
 Attention to important drug-device interactions (Goldschlager et al., 2007, p. 1253). 
According to Goldschlager et al. (2007), adverse effects are common, affecting as many as 15% 
of patients in the first year of amiodarone therapy and as many as 50% of patients during 
chronic amiodarone use. The adverse effects identified by Goldschlager et al. (2007) include 
pulmonary reactions (cough, dyspnea), gastrointestinal tract reactions (nausea, loss of appetite, 
constipation), thyroid reactions (hypothyroidism, hyperthyroidism), skin reactions (blue 
discoloration, photosensitivity), central nervous system reactions (ataxia, paresthesias, 
peripheral neuropathy, insomnia, tremors, memory impairment), ocular reactions (halo vision, 
disturbance in night vision, photophobia, blurred vision, precipitate deposits), cardiac reactions 
(bradycardia, atrioventricular blocks, arrhythmias), and genitourinary reactions (epididymitis, 
erectile dysfunction). Due to its highly lipophilic nature and slow absorption through the 
gastrointestinal tract, adverse effects may take as long as six months to resolve, necessitating 
the duteous follow-up of patients on amiodarone for signs of adverse effects (Goldschlager et 
al., 2007).  
Statement of the Problem 
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 For proper care of the patient and minimization of adverse effects of amiodarone, 
providers must be aware of the multitude of adverse effects of amiodarone and the 
recommended guidelines for monitoring. Per HRS recommendations, patients on amiodarone 
should be initially assessed every 3 to 6 months for the first year for rhythm and adverse effects 
assessment and every 6 months after the first year (Goldschlager et al., 2007). Often times, 
healthcare providers are unsure of who should be following through with the recommended 
monitoring (Bickford & Spencer, 2006). An amiodarone clinic managed by an advanced practice 
nurse could be a solution to this identified gap in patient care by providing increased adherence 
to HRS guidelines for amiodarone monitoring (Goldschlager et al., 2007).    
Data from the literature. More than 2 million prescriptions for amiodarone are written 
each year for patients (LiverTox, 2014). As many as 93% of these patients (over 1.8 million) 
develop some form of adverse reaction to amiodarone (Tafreshi, Chui, & Riley, 2009). These 
adverse reactions may be decreased through dose reduction, but as many at 2-26% of patients 
(40,000 to 520,000) require discontinuation of amiodarone due to the adverse effects (Tafreshi 
et al., 2009). Discontinuation of amiodarone then renders patients vulnerable to the arrhythmia 
that amiodarone was prescribed to control unless an alternative can be found. The most feared 
adverse drug event is pulmonary toxicity, causing death in about 10% of those diagnosed 
(Dulak, 2005).  
Amiodarone interacts with multiple medications and multiple classes of medications. The 
most serious interactions are with QT prolonging medications, causing further QT prolongation; 
digoxin, causing increased and even toxic digoxin levels; and warfarin, causing decreased 
warfarin clearance and increased risk of bleeding (Dixon et al., 2013; Dulak, 2009; O’Donovan, 
2012; Vassallo & Trohman, 2007).  
Research has shown that the implementation of an outpatient drug monitoring clinic for 
amiodarone can decrease the severity of the adverse effects and offer earlier recognition and 
treatment of the adverse effects by stricter adherence to amiodarone monitoring guidelines 
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(Bickford & Spencer, 2006; Snider, Kalbfleisch, & Carnes, 2009; Spence et al., 2011). 
Adherence to monitoring guidelines may allow for the continuation of amiodarone therapy, and 
research has shown that patient morbidity from such problems as hypothyroidism, loss of vision, 
and ataxia and mortality from such problems as pulmonary toxicity have decreased through 
earlier recognition and treatment of adverse effects (Sanoski et al., 1998; Snider et al., 2009). 
Major adverse amiodarone effects and incidence rates identified in the literature are discussed.  
Adverse effects. Patients may experience a variety of adverse events. As many as 93% 
of patients on amiodarone therapy develop an adverse drug event (Sanoski et al., 1998; 
Tafreshi et al., 2009). These events may be merely problematic such as nausea, difficulty 
sleeping, or constipation requiring only amiodarone dose adjustments, to life threatening events 
including irreversible pulmonary damage requiring immediate discontinuation of amiodarone 
(Sanoski et al, 1998; Tafreshi et al, 2009). 
Gastrointestinal. Gastrointestinal adverse drug events include hepatitis, cirrhosis, 
nausea, anorexia, and constipation. Clinical findings may include fatigue, weight loss, nausea, 
vomiting, hepatomegaly, or the patient may be completely asymptomatic. Incidence rates range 
from less than 3% to as much as 30%. (Dulak, 2005; Mackenzie, Syed, Pollak, & Koren, 2011; 
Vassallo & Trohman, 2007).  
Dermatologic. Dermatological findings may include bluish discoloration to the skin or 
photosensitivity. These clinical findings are seen with sun-exposed skin and occur in less than 
10% of patients to as many as 75% of patients (Dulak, 2005; Mackenzie et al., 2011; Vassallo & 
Trohman, 2007). 
Ocular. Corneal deposits can occur in as many as 90% of patients. Patients may also 
experience halo vision (less than 5%), poor visual acuity, or less often, changes in peripheral 
vision due to optic neuropathy (Dulak, 2005; Mackenzie et al., 2011; Vassallo & Trohman, 
2007).  
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Central nervous system. Peripheral neuropathy is experienced in 0.3% of patients 
whereas 3-30% of patients may experience ataxia, tremors, and sleep disturbances such as 
insomnia (Dulak, 2005; Mackenzie et al., 2011; Vassallo & Trohman, 2007). 
Thyroid. Around 3% of amiodarone is comprised of iodine, leading to thyroid 
dysfunction in some patients caused by the inhibition of the de-iodination of T4 to T3 
(O’Donovan, 2012; Vassallo & Trohman, 2007). Hyperthyroidism and hypothyroidism may occur 
in over 30% of patients taking amiodarone with hypothyroidism being more common. Symptoms 
may include weight loss, malaise, goiter, tremors, cold intolerance, hair loss, bradycardia, and 
tachycardia (Dulak, 2005; Mackenzie et al., 2011). 
Cardiac. Around 5% of patients may experience bradycardia when taking amiodarone 
manifested by fatigue or syncope (Dulak, 2005; Mackenzie et al., 2011). Rarely patients may 
experience arrhythmias related to amiodarone use such as torsades de pointes or 
atrioventricular block (Dulak, 2005; Mackenzie et al., 2011). 
Pulmonary. A potentially life-threatening complication of amiodarone therapy is 
amiodarone-induced pulmonary toxicity. Incidence rates range from 5-13% and mortality rates 
range from 10-23% (Ernawati, Stafford, & Hughes, 2008). Clinical findings may include acute 
onset of shortness of breath, nonproductive cough, chest pain, weight loss, and fever (Dulak, 
2005; Mackenzie et al., 2011). Patchy infiltrates may be present on chest x-ray (O’Donovan, 
2012).  
Drug/food interactions. Amiodarone is metabolized by the cytochrome P450 system in 
the liver (Mackenzie et al., 2011) and may interact with multiple medications including warfarin; 
digoxin; beta-blockers; calcium channel blockers; cyclosporine; antidepressants including 
selective serotonin reuptake inhibitors and tricyclics; antimicrobials such as macrolides, azole 
antifungals, fluoroquinolones; other antiarrhythmics such as quinidine, disopyramide, 
procainamide, flecainide, and sotalol; and statins (Dulak, 2005; Mackenzie et al., 2011; 
O’Donovan, 2012; Vassallo & Trohman, 2007). Patients should also be instructed to avoid 
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grapefruit juice due to its inhibition of the cytochrome P450 pathway leading to increased levels 
of amiodarone in the blood (O’Donovan, 2012). 
Research identification of adherence to amiodarone monitoring. Monitoring for 
amiodarone therapy is essential for early recognition and treatment of adverse effects. Bickford 
and Spencer (2006) conducted a study to assess baseline amiodarone monitoring adherence 
on hospital inpatients and adherence to continued amiodarone monitoring adherence as 
outpatients. Baseline monitoring for liver function tests, thyroid function tests, and chest x-rays 
was 87%, 82%, and 87% respectively. However, only 24% of the patients received baseline 
pulmonary function testing with only half of those including the diffusion capacity (Bickford & 
Spencer, 2006). As outpatients, only 35% of patients received liver function testing every six 
months, only 20% of patients received thyroid function testing every six months, and only 50% 
of patients received yearly chest x-rays (Bickford & Spencer, 2006).  
Stelfox et al. (2004) conducted a similar study to assess baseline amiodarone monitoring 
adherence. The researchers found that 52% of patients had baseline pulmonary function testing 
completed, 42% had baseline liver function testing, 40% had baseline thyroid function testing, 
85% had baseline electrocardiograms, and 60% had baseline chest x-rays (Stelfox et al., 2004). 
Amiodarone adverse drug events were identified in 8% of the patients during this monitoring 
period with approximately one-third of the adverse drug events deemed to be preventable with 
greater adherence to amiodarone monitoring guidelines (Stelfox et al., 2004).  
Success of amiodarone clinics. One of the best methods of decreasing potential 
adverse effects of amiodarone therapy is the use of a dedicated clinic. Sanoski et al. (1998) 
completed a study comparing amiodarone monitoring in patients before and after referral to a 
multidisciplinary amiodarone clinic. This multidisciplinary team consisted of an 
electrophysiologist, a clinical pharmacist, a cardiovascular pharmacy fellow, and 
electrophysiology nurse. The electrophysiologist’s responsibilities included acting as medical 
director and overseeing the other team members and authorizing amiodarone dose 
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adjustments. The responsibilities of the clinical pharmacist, cardiovascular pharmacy fellow, and 
electrophysiology nurse included objective and subjective patient assessment, amiodarone drug 
interaction screening, patient/staff education, and scheduling/interpretation of diagnostic testing 
(Sanoski et al., 1998). Before enrollment in the amiodarone clinic, only 23% of the patients had 
the appropriate laboratory tests performed by primary physicians with improvement to 90% once 
the patients were enrolled into the multidisciplinary amiodarone clinic (Sanoski et al, 1998).  
In 2004, Graham and colleagues conducted a similar study assessing amiodarone 
adherence rates in patients enrolled in an amiodarone monitoring clinic. This clinic was 
pharmacist-managed, rather than managed by a multidisciplinary team. Adherence to baseline 
monitoring improved for thyroid function testing, liver function testing, eye exams, and 
electrocardiograms, but not for pulmonary function testing and chest x-rays (Graham et al., 
2004).  
Snider et al. (2009) conducted a study comparing a pharmacist-led antiarrhythmic 
monitoring service with usual care. Before referral to the antiarrhythmic monitoring service, the 
researchers found that only 59% of patients had completed all the recommended diagnostic 
testing, but after enrollment into the antiarrhythmic service, 98.5% of patients had completed all 
of the recommended diagnostic testing (Snider et al., 2009). 
Johnson and colleagues (2010) conducted a similar study comparing a pharmacist-led 
amiodarone monitoring service to usual care. After enrollment into the amiodarone monitoring 
service, percentage of adherence both at baseline and for continuing monitoring increased in all 
areas of diagnostics except for chest x-rays (Johnson et al., 2010). Spence et al. (2011) 
organized a similar study examining amiodarone monitoring adherence between those enrolled 
in the pharmacist-managed amiodarone monitoring clinic and those in usual care. Adherence 
was higher in the pharmacist-managed amiodarone clinic group for baseline and continued liver 
function testing, thyroid function testing, chest x-rays, and pulmonary function testing (Spence et 
al., 2011).  
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Spence et al. (2011) organized a study examining amiodarone monitoring adherence 
between those enrolled in the pharmacist-managed amiodarone monitoring clinic and those in 
usual care. Adherence was higher in the pharmacist-managed amiodarone clinic group for 
baseline and continued liver function testing, thyroid function testing, chest x-rays, and 
pulmonary function testing (Spence et al., 2011).  
APN-led clinics. To date, no APN-led amiodarone/antiarrhythmic clinics were 
documented in the literature. However, other APN-led clinics for chronic disease/medication 
management have been successful. Chandler (2007) explored the use of a nurse-led clinic to 
reduce readmission rates for asthma. Readmission rate decreased from 22% to about 6% after 
enrollment into the nurse-led asthma clinic post hospital discharge. Hatchett (2005) outlined 
eight roles of a nurse-led clinic. These roles include “educating patients, providing psychological 
support and explanation, monitoring the patient’s condition, conducting physical assessments, 
ordering appropriated diagnostic investigations and interpretation, creating treatment plans, 
often involving other members of the multidisciplinary teams, such as GPs or primary care 
colleagues, managing medicines, empowering the patient or carer to achieve greater self-
monitoring and/or care” (Hatchett, 2005, p. 50). Patients with heart failure have also been 
successfully managed by nurses (Grange, 2005). Evaluation of nurse-led heart failure clinics 
demonstrated an improved quality of life, individualized care, appropriate medication 
management, and improved patient education as well as reduced readmission rates (Grange, 
2005). A nurse-led acute coronary syndromes clinic was found to have a significantly lower six-
month readmission rates (Alfakih et al., 2009). 
Nurses have also been used in medication management. In a 2012 study, Levine, Shao, 
and Klein compared a nurse-led warfarin monitoring service to the usual care of monitoring by a 
family physician. They found that nurse-led monitoring of warfarin was just as effective as 
physician monitoring (Levine et al., 2012). Aziz, Corder, Wolffe, and Comerota (2011) found that 
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a lower percentage of patients monitored by the anticoagulation service that was nurse-led 
required hospitalization and provided a significant cost savings.  
Data from the clinical agency. The clinical agency for this EBP project was a 
cardiology practice in northwest Indiana. The electrophysiologist employed by the practice 
expressed concern that adherence to amiodarone monitoring could use significant improvement 
(N. Nasser, personal communication, June, 2013). Currently, approximately sixty patients within 
the electrophysiology practice are on amiodarone therapy. At the clinic, all patients newly 
initiated on amiodarone receive baseline thyroid/liver function testing, a baseline 
electrocardiogram, a baseline chest x-ray, a baseline pulmonary function test, and a baseline 
eye exam. Patients on chronic amiodarone therapy receive biannual liver/thyroid function 
testing, a yearly electrocardiogram, and a yearly chest x-ray. Some patients lost to proper 
amiodarone follow-up were identified by the project manager and the electrophysiologist as 
having adverse effects of amiodarone including liver toxicity demonstrated by severely elevated 
liver function tests, pulmonary toxicity demonstrated by abnormal chest CT scans and abnormal 
pulmonary function tests, and hypothyroidism as demonstrated by elevated TSH levels. It was 
decided by the electrophysiologist that implementing an amiodarone clinic would increase 
adherence to amiodarone monitoring guidelines and allow for increased use of amiodarone in 
the practice for treatment of arrhythmias (N. Nasser, personal communication, June, 2013).  
A small-scale amiodarone monitoring clinic was initiated in August, 2013 to explore the 
benefit of an APN-led amiodarone clinic within the cardiology practice. A protocol for 
amiodarone monitoring was developed by the electrophysiologist using HRS guidelines 
(Goldschlager et al., 2007). Patients were educated on the risks and benefits of amiodarone use 
as well as the amiodarone monitoring schedule by the electrophysiologist and electrophysiology 
nurse, also serving as the EBP project manager. A patient education sheet was created 
educating patients about common adverse effects of amiodarone and the more dangerous 
effects including pulmonary toxicity. Also included on the patient education sheet was the 
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amiodarone monitoring schedule and the office number to call if any adverse effects were 
observed by patients. A more intense follow-up was conducted by the electrophysiology nurse 
to observe for both subjective and objective signs and symptoms of adverse amiodarone 
effects.         
Purpose of the EBP Project 
The purpose of this evidence-based practice (EBP) project was to assess if enrollment in 
an APN-led amiodarone clinic would change adherence to amiodarone monitoring 
recommended by best practice guidelines. Furthermore, it was hoped any adverse effects would 
be recognized in a timely manner to allow for earlier intervention to prevent patient morbidity 
and mortality from amiodarone adverse effects.   
 Identification of the compelling clinical question. The compelling clinical question 
that was hoped to be answered by this EBP project is: Does enrollment in an amiodarone clinic 
compared with “usual care” change adherence to monitoring as recommended by best practice 
guidelines and allow for earlier recognition of adverse effects of amiodarone to decrease 
negative patient outcomes over a four month time period? 
 PICOT format. This EBP project used the PICOT format to formulate the compelling 
clinical question (Melnyk & Fineout-Overholt, 2011). This format included the components of:  
 (P)atient population or disease of interest. In this project, the population of interest is 
those patients with newly initiated amiodarone therapy who are 18 years of age or older. 
 (I)ntervention or issue of interest. The patients enrolled in the amiodarone clinic based 
on HRS guidelines (Goldschlager et al., 2007) for the monitoring of amiodarone is the 
intervention of interest. 
 (C)omparison intervention or issue of interest. Those patients identified by chart review 
as the “usual care” group will be the comparison group. 
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 (O)utcome. The outcomes of monitoring adherence, identification of adverse drug 
events, and decreased negative outcomes are of interest.  
 (T)ime. The time period proposed was from September 1, 2013 to December 31, 2013. 
Significance of the Project 
Outpatient medication management clinics can be useful in monitoring those patients on 
medications which require more intense monitoring (Tafreshi et al., 2009). Subjective patient 
data can be gathered at each visit and added to the objective assessment to develop an 
assessment and plan of action to promote the best patient outcome for patients on amiodarone 
therapy (Earl & Reinhold, 2014). In order to build a strong outpatient medication management 
clinic, a strong therapeutic relationship must be built, patient health knowledge must be 
ascertained, and medication adherence must be evaluated (Earl & Reinhold, 2014). These are 
all practices that an APN is more than qualified to perform as depicted within the role 
components of clinician, consultant, educator, leader, and researcher which promote change, 
communication, critical thinking, and lifelong learning.  
Nurse-led clinics are not new to healthcare, with nurse-led clinics already established in 
the care of patients with congestive heart failure (Grange, 2005), patients with heart disease 
(Hatchett, 2005), and patients with liver disease (McAfee, 2012), just to name a few. APNs can 
provide valuable care through clinical skills that offer symptom relief, facilitation of 
interdisciplinary referrals (McAfee, 2012), as well as provide improved outcomes for patients as 
demonstrated by fewer hospital readmissions (Grange, 2005). These tasks are completed by 
the APN through the education of patients regarding their chronic conditions (Grange, 2005; 
McAfee, 2012). 
The design of this EBP project was created to show that enrollment into a nurse-led 
amiodarone clinic would enhance patient care within a specific cardiology practice and result in 
increased adherence to monitoring guidelines. Through adherence to recommended monitoring 
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guidelines, earlier recognition and treatment of adverse drug events of amiodarone would take 
place to decrease negative outcomes that may be experienced if otherwise left untreated.  
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CHAPTER 2 
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE  
This chapter includes the theoretical framework, evidence-based practice model, and 
review of literature used for guidance of the project. This project uses Imogene King’s Theory of 
Goal Attainment (King, 1971) as a theoretical framework and the ACE Star Model of Knowledge 
Transformation (Stevens, 2004) for the Evidence-Based practice model. The search engines 
used as well as the keywords and inclusion/exclusion criteria will also be discussed in this 
chapter. Once the review of literature was completed, the sources of evidence chosen were 
critically appraised to provide sustenance to the EBP project and provide guidelines for the use 
of an APN-led amiodarone clinic in the outpatient setting.  
Theoretical Framework 
Description and application of the model. In her book, Toward a Theory for Nursing: 
General Concepts of Human Behavior, Dr. King (1971) expressed the need for the 
establishment of a conceptual framework for nursing. With the explosion of evidence-based 
practice, the organization of key concepts became important, both in the advancement of 
clinical practice and in the education of future nurses. Some sort of harmony was needed 
between those responsible for patient care and those responsible for advancing research for 
clinical practice. From this, Dr. King developed her conceptual framework for nursing (King, 
1971). This framework consists of three dynamic systems (individual, group, and society) 
interacting with one another. The center of Dr. King’s conceptual framework consists of the 
personal system. This would be the individual, or patient, that the nurse interacts with. The 
patient is oriented toward achievement of goals in a dynamic manner through the guidance of 
nursing (King, 1971; King, 1981). For the purposes of this EBP project, the personal system will 
consist of the individual patient needing therapy in an APN-led clinic.   
The individual interacts with others to form the interpersonal system. This part of the 
conceptual framework focuses on interactions that take place between the patient and those 
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assisting with goal attainment. The patient participating in the EBP project will interact with the 
EBP project manager to achieve a common goal. 
The social system includes those individuals who share common goals and interests 
(Sieloff-Evans, 1991). Examples include families, religious groups, educational organizations, or 
governments (King, 1999). The social groups that patients are a part of often influence the 
patient’s perceptions. For the purposes of the EBP project, the social system might include 
whomever the patient will bring with them to the follow-up appointments with the EBP project 
manager. This might include family members or friends.   
The personal system encompasses the individual. Individuals interact with one other to 
form small groups called interpersonal systems. Groups with similar interests and goals come 
together to form organized structures, such as families and societies, called social systems 
(King, 1981). Several assumptions exist within this conceptual framework.  First, human beings 
are considered to be dynamic, open systems. This allows for constant action within the 
environment and reaction to the environment. Nursing’s focus is the interaction of patients within 
their individual environment, taking into account the perceptions each individual has of the 
environment in which they live. The common goal between nursing and the individual is to 
obtain or maintain health (Frey et al., 2002; King, 1971; King, 1981). Once individuals attain 
health, individuals have the ability to function appropriately within their societal role (Whelton, 
1999). 
In this nursing theory, nurses and patients come together, communicate information, set 
mutual goals, and take appropriate actions to attain the mutual goals. A new definition for 
nursing was created during the construction of the theory stating “nursing is a process of human 
interactions between nurse and client whereby each perceives the other and the situation; and 
through communication, they set goals, explore means, and agree on means to achieve goals” 
(King, 1981, p. 144). This new definition allowed for further expansion of patient-involvement in 
the development of treatment plans taking into account patient-individualized stressors and 
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obstacles to optimal health. In summary, the nurses and patients interact and move toward a 
common goal through the nursing process taking into account different perceptions (views) of 
the environment around them, different roles (position within the patient’s social system), and 
stress (exchange of energy between the patient and their environment) through communication 
(trade of information) and transaction (series of negotiations) (King, 1981). King purposefully 
included patients in the treatment process and encouraged them to become a part of the 
treatment plan process. Goal attainment is useful in nursing as it allows for easy validation of 
the nursing process. Goal attainment is an easily measured outcome that provides evidence of 
the usefulness of the nursing process and nursing interventions through completion of the 
mutually agreed upon goal between nurses and patients. Both patients and nurses interact and 
form a relationship to better understand one another, develop mutual goals, and develop a 
process to obtain the set goals. Both parties within the dynamic interpersonal relationship 
contribute to goal attainment and processes to obtain mutual goals. 
Application of the theoretical framework to EBP project. In this EBP project, 
improvement in amiodarone monitoring became the common goal for achievement by patients 
and the EBP project manager. Patients were the personal system. Once patients attended the 
first appointment with the EBP project manager, an interpersonal system was established. 
Through transactions as well as education of amiodarone adverse effects, the EBP project 
manager and patients decided on the mutually agreed upon goal of adherence to amiodarone 
monitoring guidelines to promote the best possible outcome of patients. Those participating in 
the patients’ care, such as family members or friends, became part of the social system, 
influencing the process to achieve goal attainment.  
Theoretical framework strengths and weaknesses. The strengths of this framework 
include its ease in adaptability to a broad range of interpersonal relationships encompassing a 
wide range of disciplines throughout the patient care process. The APN can utilize goal 
attainment in the care of a multitude of chronic and acute conditions such as heart failure, liver 
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disease, and cardiac disease. The major limitation of this framework is the dependence on the 
interpersonal relationship. A strong therapeutic relationship must be built to establish the trust 
needed by patients to facilitate mutually agreed upon goals. The successful outcome of goal 
attainment must be mutually agreed upon by each party in the interpersonal relationship. 
Without agreement and participation, goal attainment will not be achieved. In the case of the 
amiodarone clinic, the mutual goal is improved adherence to amiodarone monitoring guidelines. 
Improved monitoring adherence is achieved through patient compliance with monitoring. Patient 
compliance with diagnostic monitoring is accomplished through patient education on the 
importance of amiodarone monitoring adherence. The common goal of increased adherence to 
amiodarone monitoring allows for early identification of potential adverse drug events.  
Evidence-Based Practice Model 
Description and application of the EBP model. The ACE Star Model was chosen to 
guide this evidence-based practice project. The model originated at the University of Texas 
Academic Center for Evidence-Based Practice (ACE) (Stevens, 2004). The goals of this 
university-based program include improving patient outcomes, improving patient care, and 
improving patient safety. The objectives of ACE are to (a) advance nursing roles in the 
synthesis of evidence, translation, incorporation, and improvement science; (b) furnish a 
location for interdisciplinary evidence-based practice; (c) simplify transfer of health care 
knowledge to nursing and health care practice; (d) inspire, enable, organize, and conduct 
research and interdisciplinary inquiries in the field of evidence-based practice and quality 
improvement; (e) and offer education in evidence-based practice through the entire spectrum of 
collegiate programs as well as continuing education programs (Stevens, 2004). The ACE 
framework organizes evidence-based practice processes into a five-point star which illustrates 
the five stages of the models including discovery of research, evidence summary, translation to 
guidelines, practice integration, and evaluation (Stevens, 2004). 
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Stage 1: Discovery of research. In this stage of the ACE Star Model, original 
knowledge is exposed through research and scientific inquiry (Stevens, 2004). Results are 
generated through single studies which can range from descriptive to correlational to causal and 
from randomized control trials to qualitative studies. The purpose of this stage is to build the 
mass of research regarding clinical activities.  
 Many patients on amiodarone have not adhered to recommended monitoring guidelines 
(Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; 
Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al, 2009). Several 
studies were identified through a review of literature documenting the success of amiodarone 
clinics to improve adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 
2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi 
et al., 2009). By using discovery of research, knowledge regarding the usefulness of 
amiodarone clinics in adherence to monitoring guidelines was obtained. 
Stage 2: Evidence summary. The mass of research is combined into a single, 
significant statement. Systematic reviews are often developed in this stage as well as the 
identification of bias and effects of chance (Stevens, 2004). Evidence summary also allows for 
the recurrent update of knowledge with fresh evidence.  
 Within the current evidence, the use of outpatient amiodarone clinics has shown 
improvement in adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 2010; 
Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al, 
2009) and the earlier discovery of adverse effects of amiodarone (Johnson et al., 2010; Sanoski 
et al., 1998; Snider et al., 2009; Tafreshi et al., 2009). Most of the current research utilizes 
outpatient clinics run by pharmacists. Some amiodarone clinics were run by a multidisciplinary 
team including pharmacists, physicians, and nurses. The use of an APN-led clinic was designed 
to overcome barriers reported by the pharmacist-led amiodarone clinics. 
EFFECTS OF AN APN-LED AMIODARONE CLINIC 18 
 
Stage 3: Translation to guidelines. Translation permits evidence delivery into a 
summary of useful, relevant information termed clinical practice guidelines. This evidence may 
be located in care standards, clinical pathways, organizational protocols, and organizational 
algorithms. These guidelines represent evidence-based practices to support clinical decision-
making. Evidence is coupled with clinical expertise and theory to allow for the application of the 
evidence across a multitude of patient populations and settings (Stevens, 2004). 
 Many large healthcare organizations (Johnson et al., 2010; Raebel et al., 2006; Snider et 
al., 2009; Spence et al, 2011) have instituted outpatient drug monitoring programs to increase 
adherence to monitoring guidelines and increase the identification of adverse drug effects. 
These monitoring programs have provided data that show increased adherence to monitoring 
guidelines and the early identification of adverse drug effects. By having a monitoring program 
dedicated to amiodarone monitoring by HRS guidelines, the confusion regarding who was 
responsible for monitoring these patients was negated and allowed for the early identification of 
adverse drug effects requiring dose adjustments or possibly discontinuation of amiodarone 
(Goldschlager et al., 2007). Multidisciplinary amiodarone clinics as well as pharmacist-led clinics 
have been documented in the literature.  
Stage 4: Practice integration. Society expects healthcare professionals to remain up-
to-date on current best practices. In order to complete this task, healthcare professionals and 
organizations must be willing to accept new guidelines for practice if the evidence is supportive 
of the change (Stevens, 2004).  
 This EBP project utilized a chart review of patients prior to institution of an amiodarone 
clinic in a small northwestern Indiana cardiology practice and then another chart review of 
patients after implantation of an amiodarone clinic. Baseline monitoring as well as continuation 
of monitoring for those on chronic amiodarone therapy was compared between these two 
cohorts.  
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Stage 5: Evaluation. Evaluation is the final step in the ACE Star Model (Stevens, 2004). 
The influence of evidence-based practice on patient outcomes, healthcare professional/patient 
satisfaction, efficacy/efficiency of care, economic analysis, and health status impact were 
evaluated. For this EPB project, outcomes evaluated included the number of participants that 
completed baseline diagnostic monitoring for those newly initiated on amiodarone and the 
number of participants that completed continuation of monitoring for those on chronic 
amiodarone therapy. 
Previous studies and reviews have suggested an increase in the adherence to 
monitoring guidelines (Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski 
et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009) and the identification 
of adverse effects of amiodarone allowing for early treatment to reduce morbidity and mortality 
from the adverse effects of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 
2009; Tafreshi et al., 2009). It was hoped that these results would be duplicated in this EBP 
project.  
Strengths and limitations of the EBP model. Strengths of the ACE Star model include 
the step-by-step progression of the EBP process outlined in five-points that flows logically from 
the start of EBP in the review of literature to the end where evaluation of the EBP process 
occurs. As movement occurs through the ACE Star model, the applicability of research to 
nursing practice strengthens. Research that has accumulated in an area has been reviewed, 
summarized, and transmitted to practice with evaluation of the implementation of the EBP. A 
more succinct summary along with consistent research that is summarized allows for a more 
meaningful research review and permits the research to be applicable to many different areas of 
nursing. A limitation of the ACE Star model includes the dependence on the availability of 
research literature regarding the proposed EBP project. Without available research, the EBP 
process becomes stalled at Stage 1 (Discovery of research). A lack of research pertaining to 
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APN-led amiodarone clinics was observed, requiring the expansion of the literature search to 
include any form of nurse leadership of amiodarone clinics for this EBP project.   
Review of Literature 
Literature review. Multiple sites were used in this literature review including the 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Medline, ProQuest, the 
Joanna Briggs Institute, the Cochrane Library, Academic Search Premier, the Virginia 
Henderson International Nursing Library, and GoogleScholar (see Table 2.1). A review of the 
literature was completed using the keywords of “amiodarone, monitoring, and toxicity” which 
yielded 6 results in a CINAHL search. Medline was searched using the limiters of publication 
dates from 1995-2013, English language and the keywords of “amiodarone and monitoring” 
which yielded 286 results. Adding the limiter of toxicity yielded 42 results. A ProQuest search 
using the limiters of publications dates from 2000-2013, English language, peer reviewed, and 
the keywords of “amiodarone, toxicity, and monitoring” yielded 445 articles. A search of the 
Cochrane Library using amiodarone yielded 3 results, antiarrhythmic yielded 2 results, and 
antiarrhythmic clinic yielded 13 results. A search of the Joanna Briggs Institute using the 
keyword of amiodarone yielded no results, antiarrhythmic yielded no results, and outpatient 
yielded 3 results. One article was found using a hand search of journal publications available in 
the clinic where the project manager is employed. A search using GoogleScholar using the 
keywords of amiodarone, monitoring, toxicity, ambulatory, clinic, and multidisciplinary using the 
limiter of publication dates from 2003-2013 yielded over 600 results, 15 of which were 
applicable to this EBP project using the inclusion criteria listed below and were duplicates from 
the above search engines. Two additional articles were found through a reference list search of 
applicable articles included in this EBP project. The limiters used were expanded and narrowed 
depending on the number of results received to allow for more specificity in the review of 
literature pertaining to the EBP project.  
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Table 2.1 
Review of Literature 
Database Keywords Used Limiters 
Used 
Total 
Results 
Relevant 
to 
Project 
Duplicates Included in 
Project 
CINAHL amiodarone, 
monitoring, 
toxicity 
English 
language, 
Scholarly 
Journals 
6 2 1 1 
Medline 
amiodarone, 
monitoring  
English 
Language, 
Publication 
dates from 
1995-2013 
286 13 13 13 
Added the 
keyword toxicity 
42 9 9 0 
ProQuest amiodarone, 
monitoring, 
toxicity 
English 
language, 
publication 
dates from 
2000-
2013, peer 
reviewed 
445 1 1 0 
Joanna Briggs 
Institute 
amiodarone  0    0 
antiarrhythmic   0      0 
outpatient clinic   3 0    0 
Cochrane 
Library 
amiodarone   3 0 0 0 
antiarrhythmic   2 0 0 0 
antiarrhythmic 
clinic 
  13  0 0 0 
Academic 
Search Premier 
amiodarone, 
monitoring, 
toxicity 
English 
language, 
Scholarly 
Journals 
18 5 5 0 
Virginia 
Henderson 
International 
Nursing Library 
amiodarone   3 0 0 0 
antiarrhythmic   9 0 0 0 
ambulatory care   9 0 0 0 
Articles found 
through 
reference list 
search 
          2 
GoogleScholar 
amiodarone, 
monitoring, 
toxicity, 
ambulatory, 
clinic, 
multidisciplinary 
published 
from 2003-
2013 
617 15 14 1 
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Abstract review. The abstracts of the articles were reviewed during the literature search 
for inclusion and exclusion criteria. The inclusion criteria included (a) overall scientific value, (b) 
adult subjects, (c) relevance to the EBP project, (d) publication after 2003, (e) studied 
amiodarone/drug monitoring, (f) written in English, and (g) utilized HRS amiodarone monitoring 
guidelines (Goldschlager et al., 2007). After review of several studies that adhered to the 
inclusion criteria, the publication date limiter was extended to include articles from 1995-2003 to 
allow for the inclusion of some of the first studies of amiodarone clinics. The study by Sanoski 
and colleagues (1998) included laid the foundation for amiodarone clinics, incorporating a 
multidisciplinary team in the structure of the amiodarone clinic. Factors that excluded studies 
from inclusion in the EBP project included (a) poor data quality, (b) written in a foreign language, 
(c) did not use amiodarone within the study, (d) used subjects under the age of 18, and (e) did 
not use HRS guidelines in the monitoring protocol (Goldschlager et al., 2007). After reviewing 
the full text of the articles that met inclusion criteria and removing the duplicates, 17 articles 
were identified for use in this EBP project. The 17 sources included 7 research studies, an 
expert committee practice guideline for amiodarone monitoring, and 9 articles discussing 
background amiodarone information including mechanism of action, use, adverse effects, and 
interactions. Nine additional articles were added to solidify the usefulness of APN-led clinics.  
Describe levels of evidence. Polit and Beck’s (2012) Evidence Hierarchy was used for 
this EBP project (see Table 2.2). This hierarchy describes seven levels of evidence based on 
the strength of evidence provided. At the top of the hierarchy representing Level I evidence are 
systematic reviews of randomized control trials (RCTs) and systematic reviews of 
nonrandomized trials. Level II evidence includes single randomized control trials (RCTs) and 
single non-randomized trials. Systematic reviews of correlational/observational studies comprise 
Level III evidence. Single correlational or observational studies represent Level IV evidence. 
Level V evidence includes systematic reviews of descriptive, qualitative, or physiologic studies. 
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Single descriptive, qualitative, or physiologic studies signify Level VI evidence. At the bottom of 
this hierarchy are expert opinions of evidence representing Level VII evidence. 
Table 2.2 
Hierarchy of Evidence 
Hierarchy of evidence (Polit & Beck, 2012) Articles included in 
project 
Level I: 
a. Systematic review of randomized controlled trials 
(RCTs) 
b. Systematic review of non-randomized trials 
0 
Level II: 
a. Single RCT 
b. Single nonrandomized trial 
1(a) 
Level III:  
Systematic review of correlational/observational studies 0 
Level IV:  
Single correlational/observational study 5 
Level V: 
Systematic review of descriptive/qualitative/physiologic 
studies 
0 
Level VI: 
Single descriptive/qualitative/physiologic study 1 
Level VII: 
Opinions of authorities, expert committees 1 
 
Appraise relevant evidence. Once the review of literature was obtained and articles 
were chosen that met inclusion criteria, a thorough appraisal was completed on each source of 
evidence used for the EBP project. These appraisals were completed utilizing guidelines as 
outlined by Melnyk and Fineout-Overholt (2011). The appraisal tools included the Rapid Critical 
Appraisal Checklist for Randomized Clinical Trials, the Rapid Critical Appraisal Checklist for 
Cohort Studies, the Rapid Critical Appraisal Checklist for Qualitative Evidence, and the Rapid 
Critical Appraisal Checklist for Evidence-Based Clinical Practice Guidelines (Melnyk & Fineout-
Overholt, 2011) (see Table 2.3).  
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Table 2.3 
Evidence Appraisal 
Citation Purpose Sample Design Measurement Results/Findings 
Evidence Level 
and Appraisal 
Bickford, C. L. 
& Spencer, A. 
P. (2006).  
Quantification of 
adherence to 
published 
recommendations 
for baseline 
monitoring when 
initiating inpatient 
amiodarone 
therapy at a 
university teaching 
hospital and 
determine whether 
appropriate serial 
monitoring of 
chronic 
amiodarone 
therapy is 
occurring in the 
outpatient setting. 
45 patients 
admitted as 
inpatients at 
the Medical 
University of 
South 
Carolina 
(MUSC) who 
received 
amiodarone 
between 
November 1, 
2003 and 
March 31, 
2004.   
 
20 patients 
with an 
MUSC 
outpatient 
provider who 
had received 
amiodarone 
therapy for at 
least 6 
months. 
Retrospective 
review of 
medical 
records 
45 inpatients had 
their medical 
record reviewed 
to identify whether 
baseline liver 
function tests 
(LFTs), thyroid 
function tests 
(TFTs), chest x-
ray (CXR), and 
pulmonary 
function tests 
(PFTs) were 
completed.  
 
20 outpatients 
had medical 
records reviewed 
to evaluate if 
baseline LFTs, 
TFTs, CXR, and 
PFTs were 
completed and 
the number of 
patients who had 
received LFTs 
and TFTs every 6 
months, and  
yearly CXRs. 
Inpatients- 87% 
received baseline 
LFTs, 82% received 
baseline TFTs, 87% 
received baseline 
CXRs, and 24% 
received PFTs.  
 
Outpatients - 95% 
had received baseline 
LFTs, 75% had 
received baseline 
TFTs, 75% had 
received baseline 
CXRs, and 30% had 
received baseline 
PFTs. Only 35% of 
patients had LFTs 
every 6 months, 20% 
of patients had TFTs 
every 6 months, and 
50% of patients had 
yearly CXRs.  
Level VI 
 
Data review 
was limited to 
available files 
and did not 
include outside 
records.  
 
Descriptive 
statistics were 
applied to 
obtain 
adherence to 
monitoring and 
results 
collected are 
similar to other 
studies, 
indicating a 
need for 
dedicated 
amiodarone 
clinics.  
EFFECTS OF AN APN-LED AMIODARONE CLINIC     25 
 
Goldschlager, 
N., Epstein, A. 
E., Naccarelli, 
G. V., 
Olshansky, B., 
Singh, B., 
Collard. H. R., 
& Murphy, E. 
(2007). 
Recommendation 
for amiodarone 
diagnostic 
monitoring  
  Clinical 
practice 
guideline with 
approval by 
the HRS 
Board of 
Trustees  
    Level VII 
 
Based on 
evidence-
based 
data/clinical 
experience. 
Research 
funding not 
reported.  
Literature is 
included within 
one year of 
publication. 
Levels of 
evidence were 
not identified. 
Amiodarone 
monitoring 
guidelines are 
discussed with 
treatment of 
adverse events 
and need for 
referral 
allowing for 
easy 
completion by 
providers.  
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Graham, M. 
R., Wright, M. 
A., & Manley, 
H. J. (2004).  
To determine 
whether 
adherence to 
monitoring 
guidelines 
improved as a 
result of the 
development and 
implementation of 
an amiodarone 
monitoring clinic 
(AMC). 
225 patients 
were 
included in 
this study - 
154 in the 
intervention 
group and 71 
in the control 
group.   
Retrospective 
cohort study 
Those patients in 
the intervention 
(pharmacist-
managed 
program) cohort 
and the usual 
care cohort were 
compared for 
adherence to 
testing during the 
12 months after 
the initiation of the 
AMC. 
For baseline 
diagnostics, the AMC 
improved compliance 
for some of the 
diagnostics. 
AMC 
- PFT - 12% 
- CXR - 18% 
- TFT - 36% 
- LFT - 40% 
- Eye Exam - 30% 
- EKG - 41% 
Usual Care 
- PFT - 15% 
- CXR - 24% 
- TFT - 32% 
- LFT - 31% 
- Eye Exam - 15% 
- EKG - 32% 
 
The AMC improved 
compliance with 2 of 
the 3 continued 
monitoring guidelines. 
AMC 
- TFTs - 66% 
- LFTs - 69%3.  
Usual care 
- TFTs - 37% 
- LFTs - 38% 
- EKG monitoring was 
not shown to be 
significantly improved 
by the AMC 
Level IV 
 
Follow-up was 
sufficient to 
give data for 
the 
amiodarone 
clinic cohort 
and a specific 
timeline is 
discussed. The 
diagnostics 
completed 
were objective 
to remove 
bias, leading to 
valid study 
results. 
Statistical 
testing was 
completed to 
compare 
demographic 
data and 
adherence to 
baseline as 
well as 
continued 
amiodarone 
monitoring.   
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Johnson, S. 
G., Canty, K., 
Billups, S., & 
Schimmer, J. 
(2010).  
To determine 
whether patients 
enrolled in a 
centralized 
amiodarone 
monitoring service 
(AMS) were more 
adherent to 
amiodarone 
monitoring 
guidelines and  
 
To determine if the 
incidence of 
amiodarone-
related toxicity 
differed for 
patients enrolled in 
the AMS. 
905 patients 
were 
included in 
the study - 
518 in the 
control 
cohort and 
387 in the 
AMS cohort.  
Retrospective 
longitudinal 
cohort design 
Control and AMS 
cohorts were 
compared in 
regards to 
baseline liver 
function tests 
(LFTs), thyroid 
function tests 
(TFTs), chest x-
ray (CXR), and 
electrocardiogram 
(EKG) and 
appropriate 
follow-up interval 
testing 
Baseline testing 
Control cohort  
LFTs 44%, TFTs 
49%,CXR 56%, EKG 
58% 
AMS cohort 
LFTs 69%, TFTs 
55%,CXR 45%, EKG 
76% 
 
6 month follow-up 
testing 
Control cohort 
LFTs 76%, TFTs 70% 
AMS cohort 
LFTs 86%, TFTs 74% 
 
1 year follow-up 
testing 
Control cohort 
LFTs 69%, TFTs 
64%,CXR 71%, EKG 
75% 
AMS cohort 
LFTs 84%, TFTs 
68%, CXR 53%, EKG 
89%.  
 
Statistical significance 
was found in LFT and 
EKG monitoring only. 
Level IV 
 
Follow-up was 
sufficient to 
give data for 
the 
amiodarone 
clinic cohort 
and a specific 
timeline is 
discussed. 
Objective 
diagnostics 
removed bias, 
Statistical 
testing was 
completed to 
compare 
demographic 
data and 
adherence to 
baseline as 
well as 
continued 
amiodarone 
monitoring. 
EFFECTS OF AN APN-LED AMIODARONE CLINIC     28 
 
Raebel, M. A., 
Chester, E. 
A., Newsom, 
E. E., Lyons, 
E. E., 
Kelleher, J. 
A…Magid, D. 
J. (2006).  
To determine if 
using an electronic 
tool effectively 
increases the 
percentage of 
patients receiving 
laboratory 
monitoring during 
ongoing drug 
therapy. 
All adult 
members of 
the 
outpatient 
Kaiser-
Permanente 
Colorado 
medical 
offices were 
eligible for 
the study. 
Patients 
were 
included in 
the study if 
taking at 
least one of 
the study 
medications. 
A total of 
9139 
patients were 
included. 
Randomized 
trial 
Usual-care group 
(control group) 
was compared to 
the intervention 
group. The 
intervention 
consisted of an 
electronic alert to 
pharmacists that a 
lab result was 
missing based on 
established 
guidelines. 
Pharmacists then 
ordered missing 
lab tests, 
reminded patients 
to undergo tests, 
reviewed lab 
results and 
managed any 
abnormal results.  
For amiodarone, 71% 
of patients in the 
intervention group 
versus 55% of 
patients in the control 
group were 
appropriately 
monitored according 
to guidelines 
representing 
significant 
improvement in 
amiodarone 
adherence.  
Level IIa 
 
Participants 
were randomly 
assigned, 
random 
assignment 
was concealed 
to participants 
and providers, 
and groups 
were similar 
based on 
statistical 
testing. It was 
not reported 
whether or not 
all participants 
completed the 
study.   
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Sanoski, C. 
A., Schoen, 
M. D., 
Gonzalez, R. 
C., Avitall, B., 
& Bauman, J. 
L. (1998).  
Review the 
rationale and 
development of a  
multidisciplinary 
amiodarone clinic 
 
Document the 
clinical outcomes 
resulting from 
implementation of 
the amiodarone 
clinic. 
60 patients 
were 
enrolled in 
the 
amiodarone 
clinic and 
adherence to 
monitoring 
guidelines 
was 
compared 
before 
enrollment 
into the 
amiodarone 
clinic and 
after 
enrollment. 
Retrospective 
chart review 
In a sample of 60 
patients,  
adherence to 
monitoring 
guidelines was 
compared before 
and after 
enrollment in the 
amiodarone clinic 
Before enrollment into 
the amiodarone clinic, 
23% of the patients 
were adherent to 
monitoring guidelines. 
After enrollment, 90% 
were adherent to 
monitoring guidelines.  
 
Previously 
unrecognized 
adverse events were 
detected in 35% of 
the patients enrolled 
into the amiodarone 
clinic. 
Level IV 
 
Follow-up was 
sufficient to 
give data for 
the 
amiodarone 
clinic cohort, 
the diagnostics 
completed 
were objective, 
and statistical 
testing was 
used to 
compare 
adherence to 
monitoring 
guidelines 
before and 
after referral to 
the 
amiodarone 
clinic.  
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Snider, M., 
Kalbfleisch, 
S., & Carnes, 
C. A. (2009).  
To monitor 
antiarrhythmic 
drug therapy to 
improve the 
continuity and 
consistency of 
care for patients 
receiving class I or 
class III 
antiarrhythmic 
drugs. 
134 patients 
receiving 
amiodarone, 
sotalol, 
dofetilide, 
and 
propafenone 
who were 
referred to 
an 
arrhythmic 
medications 
clinic in 
Columbus, 
Ohio 
between July 
2007 and 
April 2008. 
Retrospective 
chart review 
Patient's 
diagnostic testing 
completion before 
enrollment was 
compared to post 
enrollment 
adherence to 
diagnostic testing 
according to 
monitoring 
protocols. 
Pharmacist 
monitoring appeared 
to improve patient 
adherence to 
recommended testing 
protocols (98.5% 
compliance versus 
59% before 
enrollment in the 
clinic). 
 
Pharmacist 
monitoring of 
outpatient 
antiarrhythmic 
medication therapy 
appeared to help 
identify adverse 
events and clinically 
significant drug 
interactions.   
Level IV 
 
Inspected the 
same group of 
patients before 
and after 
enrollment into 
an 
antiarrhythmic 
monitoring 
clinic over a 
ten month 
period. Data 
were analyzed 
using the 
Fisher exact 
test or chi 
square testing 
to remove bias 
and led to valid 
study results. 
Since the 
same group of 
participants 
comprised the 
two cohorts, 
demographics 
bias was 
eliminated.      
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Spence, M. 
M., Polzin, J. 
K., 
Weisberger, 
C. L., Martin, 
J. P., Rho, J. 
P, & Willick, 
G. H. (2011).  
To assess rates of 
lab monitoring of 
liver, thyroid, and 
pulmonary 
function and 
adverse events in 
a pharmacist-
managed 
amiodarone 
monitoring 
program 
compared with 
usual care 
 
To estimate the 
return on 
investment from 
this intervention 
2292 
patients who 
received at 
least 100 
days of 
amiodarone 
from June 1, 
2007 through 
May 31, 
2009. 181 
patients were 
in the 
intervention 
cohort and 
2111 were in 
the usual 
care cohort.  
Retrospective 
cohort study 
Those patients in 
the intervention 
(pharmacist-
managed 
program) cohort 
and the usual 
care cohort were 
compared for 
adherence to 
testing at any time 
during the year 
after the initiation 
of amiodarone 
Amiodarone program 
- LFT 
Baseline - 84% 
6 months - 84.5% 
1 year - 75.7% 
 - TFT 
Baseline - 70.2% 
6 months - 81.8% 
1 year - 77.3% 
- PFT 
Baseline - 6.6% 
Within 1 year - 51.9% 
 
Usual care 
-LFT 
Baseline - 76.3% 
6 months - 69.7% 
1 year - 61.5% 
- TFT 
Baseline - 62.7% 
6 months - 50.2% 
1 year - 46.8% 
-PFT 
Baseline - 3.6% 
within 1 year - 14% 
 
A 200% return 
investment was 
demonstrated with 
the pharmacist-
managed program. 
Level IV 
 
Follow-up was 
sufficient to 
give data for 
the 
amiodarone 
clinic cohort 
and a specific 
timeline is 
discussed. 
Objective 
diagnostics 
removed bias 
and statistical 
testing was 
completed to 
compare 
demographic 
data and 
adherence to 
baseline as 
well as 
continued 
amiodarone 
monitoring. 
Randomization 
did not occur.   
EFFECTS OF AN APN-LED AMIODARONE CLINIC 32 
 
Critical appraisal of the RCT. Several questions were utilized as identified by Melnyk 
and Fineout-Overholt (2011) when critically appraising RCTs. These questions included 
assessment of (a) the validity of the study results, (b) the results including intervention/treatment 
effect, and (c) the applicability of the results to clinical practice. 
Raebel and colleagues (2006) completed a study using an electronic tool to alert 
pharmacists to missing laboratory testing of patients on medications requiring routine laboratory 
monitoring based on published guidelines established by pharmacists and physicians. The 
percentage of patients who completed the laboratory testing was compared between the 
intervention and usual care groups using the x2 test. Out of 160 patients in the intervention 
group, 114 (71%) completed the recommended testing compared to 161 patients in the usual 
care group, 89 (55%) of whom completed the recommended testing (p < .01). The analyses 
were completed using SAS software. The electronic tool used to remind pharmacists to order 
recommended testing increased the percentage of patients who received laboratory monitoring. 
This computerized tool may be a useful addition to an amiodarone clinic as exemplified by the 
increased number of patients on amiodarone who received recommended testing. 
This RCT represents Level IIa evidence (Raebel et al., 2006). The study results were 
valid since (a) the study participants were randomly assigned to the experimental and control 
groups, (b) the random assignment was concealed from those enrolling participants into the 
study, (c) the participants and providers were blinded to the study group, (d) the study was 
completed over a year time period, (e) the participants were analyzed in their respective group, 
and (f) the participants in each group were similar based on statistical testing. It was not 
reported whether or not all participants completed the study.   
Critical appraisal for the cohort studies. The questions identified by Melnyk and 
Fineout-Overholt (2011) in the critical appraisal of cohort studies include (a) the validity of the 
study results, (b) the results including the strength of association between the exposure and 
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outcome, and (c) the applicability of the results to clinical practice. These Level IV studies are 
discussed below in chronological order of publication date.  
Sanoski, Schoen, Gonzalez, Avitall, and Bauman (1998) developed the first documented 
multidisciplinary amiodarone monitoring clinic. Sixty patients were referred to the amiodarone 
clinic. Comparison was made in adherence to monitoring guidelines before and after enrollment 
into the amiodarone clinic. Before enrollment in the amiodarone clinic, only 14 (23%) of the 
patients received appropriate monitoring as compared to 54 (90%) after enrollment in the 
amiodarone clinic. The authors also reported that previously undiagnosed adverse events were 
found in 21 (35%) of the patients enrolled in the amiodarone clinic. The researchers concluded 
that a multidisciplinary amiodarone clinic improves patient outcomes by monitoring for early 
recognition of medication-related toxicities and modifying medication dosage as indicated.  
Participants were evaluated before and after referral to the amiodarone clinic (Sanoski et 
al., 1998). Follow-up was sufficient to give data for the amiodarone clinic cohort, although a 
specific timeline was not discussed within the report. The diagnostics completed were objective 
to remove bias, leading to valid study results. Chi-square testing was used to compare 
adherence to monitoring guidelines before and after referral to the amiodarone clinic. Not only 
did appropriate monitoring increase, but also the diagnosis of previously unrecognized adverse 
effects and amiodarone dose decreased or were discontinued depending on the severity of the 
adverse effects.  
Graham, Wright, and Manley (2004) hypothesized that an amiodarone management 
clinic would improve adherence to published monitoring guidelines. In a retrospective chart 
review, the authors compared those patients enrolled in the amiodarone management clinic with 
those receiving usual care. Data obtained from the two cohorts (154 patients in the amiodarone 
management clinic group and 71 patients in the standard medical care group) were compared 
using x2 or Fisher’s exact test. No statistically significant differences were found in baseline 
monitoring adherence, but those patients enrolled in the amiodarone clinic were more likely to 
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adhere to monitoring guidelines for follow-up thyroid and liver function tests, eye examinations, 
and electrocardiograms. The authors also identified those patients taking interacting 
medications and compared adverse effects of these medications with amiodarone in both 
groups. The only significant finding was those patients taking warfarin were monitored more 
closely in the amiodarone management clinic group. It was hoped by the authors that the 
amiodarone management clinic would prove to identify adverse effects earlier to allow for 
prompter treatment of adverse effects, but differences between the groups did not allow for 
significant results. The standard medical care group took amiodarone for an average of one 
year where those enrolled in the amiodarone management clinic took amiodarone for an 
average of two years.  
This study included two groups of participants, one group was evaluated as a “usual 
care” group and another group was those enrolled in the amiodarone clinic (Graham et al., 
2004). Follow-up was sufficient to give data for the amiodarone clinic cohort; a specific timeline 
of one year post implementation of the amiodarone clinic was discussed. The diagnostics 
completed were objective to remove bias, leading to valid study results. Statistical testing was 
completed to compare demographic data and adherence to baseline as well as continued 
amiodarone monitoring.   
Snider, Kalbfleisch, and Carnes (2009) compared compliance of antiarrhythmic 
laboratory monitoring before and after enrollment into a pharmacist-led antiarrhythmic 
monitoring clinic. In a retrospective chart review, the authors found that 59% of the patients 
were compliant with all recommended laboratory and diagnostic testing before enrollment into 
the clinic and compliance increased to 98.5% after the initial clinic visit. Amiodarone was 
reported to have the highest rate of detected adverse events that were previously unrecognized. 
The conclusion was reached that implementation of a pharmacist-led antiarrhythmic monitoring 
clinic was associated with an improvement in patient adherence to monitoring guidelines and 
earlier recognition of adverse drug events. 
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This retrospective chart review inspected the same group of patients before and after 
enrollment into an antiarrhythmic monitoring clinic over a ten month period (Snider et al., 2009). 
Data were analyzed using the Fisher exact test or x2 testing to remove bias and led to valid 
study results. Since the same group of participants comprised the two cohorts, demographics 
bias was eliminated.      
Johnson, Canty, Billups, and Schimmer (2010) compared those patients receiving usual 
care to those patients enrolled in a pharmacist-led amiodarone management service using a 
retrospective cohort design. Adherence was defined as completing baseline, six month, and 12 
month monitoring per recommended guidelines for liver and thyroid function test as well as 
baseline and yearly chest x-rays and electrocardiograms (EKGs). Monitoring adherence rates 
between the two groups were compared using x2 testing. The amiodarone monitoring service 
group had better adherence rates for liver/thyroid function monitoring and EKG monitoring but 
was statistically significant for liver function monitoring and EKG monitoring only. The authors 
also identified that the amiodarone monitoring service group had significantly lower adverse 
drug events (21 events in the amiodarone monitoring service group as compared to 48 events in 
the usual care group).  
Two groups of participants were included in the study design (Johnson et al., 2010); one 
group was evaluated before the amiodarone clinic was implemented and the other group 
included those enrolled in the amiodarone clinic. Follow-up of four years for each group was 
sufficient to give data for each cohort. Objective diagnostics removed bias, x2 statistical testing 
was completed to compare demographic data and adherence to baseline as well as continued 
amiodarone monitoring.    
The most recent amiodarone monitoring clinic found in the literature search was a study 
conducted by Spence et al. (2011). This study’s objective was to compare rates of laboratory 
monitoring of liver, thyroid, and pulmonary function as well as adverse drug events in a 
pharmacist-led amiodarone clinic as compared to usual care using a retrospective cohort study 
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design. Monitoring rates were compared using x2 tests. Results showed that monitoring rates for 
liver and thyroid function at baseline and follow-up were significantly higher in the pharmacist-
led amiodarone group as well as the obtainment of baseline chest x-rays. It was also shown that 
patients in the amiodarone clinic were less likely to be hospitalized for adverse drug events as 
compared to the usual care group leading the authors to hypothesize that a positive return on 
investment may be experienced from implementation of an amiodarone clinic.  
This study also included two groups of participants; one group consisted of those 
participants who were seen in the medical centers without the amiodarone clinic and the other 
group consisted of those participants who were seen in the medical centers with the 
amiodarone clinic (Spence et al., 2011). Follow-up was conducted over a two year period, which 
was sufficient to give data for the amiodarone clinic cohort. Objective diagnostics removed bias 
and x2 statistical testing was completed to compare demographic data and adherence to 
baseline as well as continued amiodarone monitoring. Randomization of participants did not 
occur as selection for the groups was based on which medical center participants used.   
All of these studies included in the review of literature utilized retrospective chart reviews 
of non-randomized subjects leading to a lower level of evidence and bias. Multiple factors 
included selection bias, inadequate sample size, and disproportionate cohort sizes. 
Nonetheless, the data included did show clinical significance and provided evidence of 
improved patient outcomes through implementation of a monitoring clinic for amiodarone.  
Critical appraisal for the descriptive study. This study was included as evidence in 
order to provide additional literature regarding the inobservance of monitoring guidelines. 
Guidelines for critical appraisal of qualitative evidence were used to critically appraise this Level 
VI study (Melnyk & Fineout-Overholt, 2011) and included (a) the validity of the study results, (b) 
the quality of the description of the findings, and (c) the applicability of the results to clinical 
practice. A nonrandomized sample was included in this study; all patients meeting inclusion 
criteria were included. 
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In 2006, a study was published comparing institutional adherence to recommended 
guidelines for the monitoring of amiodarone therapy. Bickford and Spencer (2006) completed a 
retrospective chart review for both inpatients and outpatients at a medical university and found 
that of the 45 inpatients initiated on chronic amiodarone therapy, only 5 (11%) completed all of 
the recommended baseline diagnostic testing. Twenty outpatients were identified on chronic 
amiodarone therapy. The number of patients completing all of the recommended baseline 
diagnostic testing was not reported. Baseline liver function tests (LFTs) were completed in 95% 
of the patients, thyroid function tests (TFTs) were completed in 75% of the patients, chest x-rays 
(CXRs) were completed in 75% of the patients, and pulmonary function tests (PFTs) were 
completed in 30% of the patients. Only 35% of the patients completed a six month LFT, 20% 
completed TFTs, and 50% completed a CXR. The authors hypothesized that adherence to 
recommended amiodarone monitoring guidelines might be enhanced through electronic 
reminders to order appropriate diagnostic testing, the implementation of amiodarone protocols, 
or the implementation of multidisciplinary amiodarone monitoring clinics.  
The convenience sample of patients was taken over a five month period to assess 
adherence to amiodarone diagnostic monitoring (Bickford & Spencer, 2006). The data review 
was limited to files available within the hospital database and did not include outside records. 
Descriptive statistics were applied to obtain adherence to monitoring. The results collected were 
similar to other studies included in the literature review, indicating a need for dedicated 
amiodarone clinics.  
Critical appraisal for the clinical practice guideline. The HRS guidelines for 
amiodarone monitoring were chosen as the clinical practice guideline this EBP project 
(Goldschlager et al., 2007). These guidelines were developed based on evidence-based data 
and clinical experience of the writing committee in the care of patients taking amiodarone. 
According to Melnyk and Fineout-Overholt (2011), clinical practice guidelines should be 
appraised for credibility and applicability/generalizability. It is unknown whether the guidelines 
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developers were funded researchers of the reviewed studies for the clinical practice guidelines. 
Literature was included in the reference list within one year of publication of the updated clinical 
practice guidelines. Levels of evidence of the literature review were not identified within the 
guidelines. Amiodarone monitoring guidelines are discussed as well as recommendations for 
treatment of adverse events and referral recommendations. This guideline was approved by the 
HRS Board of Trustees. These amiodarone monitoring guidelines provide a schedule for 
amiodarone monitoring as well as a blueprint for follow-up of patients taking amiodarone, 
complete with subjective and objective signs and symptoms of amiodarone adverse effects. The 
diagnostic testing recommended for amiodarone monitoring can easily be completed by 
providers.  
Construct EBP 
Literature Synthesis. The literature documents that initiation of an amiodarone clinic 
not only increases adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 
2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011, Tafreshi 
et al., 2009) as recommended by the Heart Rhythm Society (Goldschlager et al., 2007), but also 
increases early recognition of adverse events (Johnson et al., 2010; Sanoski et al., 1998; Snider 
et al., 2009; Tafreshi et al., 2009) (see Table 2.3). The benefit of earlier recognition of adverse 
events is the extent of morbidity and mortality due to amiodarone toxicity can be lessened 
through dose reduction or discontinuation of amiodarone if needed (Johnson et al., 2010; 
Sanoski et al., 1998; Snider et al., 2009). 
Description of best practice model recommendation. The amiodarone monitoring 
guidelines (see Table 2.4) used in this EBP project were modeled after the guidelines 
recommended by the HRS. According to HRS guidelines (Goldschlager et al., 2007), certain 
diagnostic testing is recommended before initiation of amiodarone and at certain intervals 
throughout amiodarone therapy. Testing includes baseline liver function tests (LFTs), thyroid 
function tests (TFTs), pulmonary function tests (PFTs) including DLCO (diffusion capacity for 
EFFECTS OF AN APN-LED AMIODARONE CLINIC 39 
 
carbon monoxide), chest x-ray (CXR), electrocardiogram (EKG), and a thorough eye exam. Not 
only do these serve as a baseline data for the patient for comparison in the future, but these 
baseline diagnostics also aid in the identification of those at higher risk for development of 
adverse effects of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009). 
In addition, the clinic was led by an APN to assess the effectiveness of this type of clinic 
management for increasing adherence to monitoring guidelines and the reduction in adverse 
events. After discussion with the electrophysiologist who assisted with the development of the 
monitoring protocol, it was decided International Normalized Ratios (INRs) would be followed 
weekly for six weeks after initiation of amiodarone due to amiodarone’s potentiation of warfarin. 
All of the participants in the study who were on warfarin in conjunction with amiodarone were 
followed in a Coumadin clinic, negating the necessity for the project manager to see the 
participants on a weekly basis. 
Table 2.4 
HRS Recommended Amiodarone Monitoring Protocol 
Diagnostic test When test is completed 
Liver function test (AST, ALT) Baseline and every 6 months 
Thyroid function test (TSH, FT4 if indicated) Baseline and every 6 months 
Chest x-ray Baseline and yearly 
Pulmonary function test (with DLCO) Baseline and as needed for suspicion for 
pulmonary toxicity 
Eye exam Baseline and as needed for suspicion of eye 
impairments 
Electrocardiogram Baseline and yearly 
Digoxin monitoring After amiodarone loading and as needed for 
signs of digoxin toxicity 
Warfarin monitoring Weekly for six weeks then based on results 
Note. AST = aspartate transaminase; ALT = alanine transaminase; TSH = thyroid stimulating 
hormone; FT4 = free thyroxine; DLCO = diffusing capacity of the lungs for carbon monoxide 
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Adherence to monitoring guidelines. A review of the literature showed that those 
patients receiving amiodarone are not being monitored as recommended by Heart Rhythm 
Society guidelines (Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; 
Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; and Spence et al., 2011). 
Implementation of specialized clinics dedicated to the monitoring of amiodarone at appropriate 
intervals has been shown to increase compliance to guidelines (Graham et al., 2004; Johnson 
et al., 2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; and Spence et al., 
2011) as well as increase earlier recognition of adverse events otherwise unnoticed (Snider et 
al., 2009; Sanoski et al., 1998; and Spence et al, 2011).   
Application of the APN role. Certain limitations have been identified in previous studies 
that would be inapplicable in the APN-led clinic. The limitations identified were found in the 
pharmacist-led amiodarone clinics and pertained to the ordering of EKGs and CXRs. 
Pharmacists are limited to the ordering of laboratory tests only and relied upon the patient’s 
primary physician to order the other diagnostics needed for monitoring guidelines (Johnson et 
al., 2010; Spence et al., 2011). In Indiana, an APN has the ability to order not only the 
laboratory diagnostics, but also other diagnostics such as EKGs, CXRs, and PFTs (Phillips, 
2005). Thus, the use of an APN-led clinic would resolve the issue of ordering diagnostic testing 
found in pharmacist-led amiodarone clinics. Naylor and Kurtzman (2010) discussed the use of 
nurse practitioners in delivering high quality care. They found that the care provided was 
comparable with care delivered by physicians and in some instances, better with regards to 
patient follow-up; patient satisfaction; and more improved screening, assessment, and 
counseling (Naylor & Kurtzman, 2010), qualities which provide for a successful amiodarone 
monitoring clinic.  
Answering the clinical question. The clinical question put forth in this EBP project was 
constructed using the PICOT format outlined by Melnyk and Fineout-Overholt (2011). The 
clinical question addressed by this EBP project was: What effects will an APN-led outpatient 
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amiodarone clinic have on adherence to amiodarone monitoring guidelines in the adult 
population over four months? In order to answer this clinical question, a practice change was 
implemented within a cardiology practice which encompassed an amiodarone clinic managed 
by an APN using HRS guidelines (Goldschlager et al., 2007). A comparison of adherence to 
amiodarone monitoring guidelines was completed using a chart review of two cohorts, one 
before initiation of an amiodarone clinic, and one after the practice change of implementation of 
an amiodarone clinic.  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
Participants and Setting 
 A northern Indiana cardiology practice was chosen as the site for the implementation of 
the evidence-based practice (EBP) project. The purpose of this project was to compare patient 
adherence to recommended HRS monitoring guidelines for amiodarone (Goldschlager et al., 
2007). This practice serves two different sites in the area with monthly patient volumes of 
around 100 patients. Participants included a convenience sample of patients newly initiated on 
amiodarone therapy during a consultation with the electrophysiologist at either site during the 
EBP project. Information was gathered from a chart review completed by the EBP project 
manager after initiation of the APN-led clinic and was compared to data collected from a chart 
review of participants receiving amiodarone during the previous year.   
 Before beginning the EBP project, neither site had a drug-monitoring program. The 
cardiology staff would initiate recommended diagnostic testing prior to amiodarone initiation as 
well as maintenance diagnostic testing. According to HRS guidelines, maintenance diagnostic 
testing consisting of LFTs and TFTs should occur at least every six months and a CXR should 
be performed at least yearly in all patients taking amiodarone (Goldschlager et al., 2007). Often 
times, a stable patient may only be seen by this cardiology practice every one to two years, 
increasing the likelihood that adherence to monitoring guidelines would be lost.  
Outcomes 
 The primary outcome of this EBP project was a comparison to adherence to 
recommended HRS monitoring guidelines of amiodarone before and after implementation of an 
amiodarone clinic in an effort to identify adverse drug events and decrease negative outcomes 
(Goldschlager et al., 2007). A chart review of patients participating in the amiodarone clinic was 
compared to a chart review of patients seen in the cardiology clinic in 2012. A secondary 
outcome was to identify decreased morbidity and mortality associated with amiodarone use due 
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to the projected increased of adherence to monitoring guidelines and early recognition of 
adverse effects after participation in the amiodarone clinic.  
Planning 
 The foundation for the evidence-based practice project started with a discussion of the 
proposed amiodarone clinic with the electrophysiologist of the practice and the practice 
manager. Both welcomed the idea of the proposed amiodarone clinic as an enhancement of 
patient care. Collaboration with the electrophysiologist took place to construct a patient teaching 
information sheet (see Appendix A), establish a protocol for initial and maintenance amiodarone 
monitoring based on HRS guidelines (see Table 2.4), and develop a standard 
subjective/objective assessment protocol (see Appendix B) for use in the amiodarone clinic 
(Goldschlager et al., 2007). After discussion with the EBP academic advisor, it was decided that 
a chart review would be more appropriate for the project and the amiodarone clinic would be 
initiated by the cardiology practice staff.   
Intervention 
 Participants in the amiodarone clinic completed initial diagnostic testing based on HRS 
guidelines at the time of amiodarone initiation (Goldschlager et al., 2007). Baseline testing 
consisted of LFTs and TFTs as well as a chest x-ray that were often times completed the day of 
consultation. The participant was then scheduled for a PFT at the participant’s earliest possible 
convenience. A follow-up visit was scheduled with the cardiology staff shortly after completion of 
the diagnostic testing to discuss the results of the initial diagnostic testing, perform further 
participant teaching regarding the use of amiodarone and its potential adverse effects, evaluate 
for compliance of amiodarone loading if applicable and ensure maintenance dose was started, 
and answer any questions the participant may have regarding amiodarone use and side effects. 
More intensive monitoring of known medication interactions was discussed with the participant if 
needed. Based on HRS guidelines, weekly monitoring of INRs for the first 4-6 weeks post 
amiodarone initiation is recommended to assess for interactions between amiodarone and 
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warfarin and allow for warfarin dose modification (Goldschlager et al., 2007). HRS guidelines 
also recommend more frequent digoxin levels during the concomitant use of amiodarone and 
digoxin (Goldschlager et al., 2007). Another visit was scheduled one month after the initial visit 
with the cardiology staff to evaluate the participant for adverse effects and evaluate for 
compliance of amiodarone therapy and adherence to monitoring guidelines. Participants were 
encouraged to call as needed for suspicion of adverse effects of amiodarone for cardiology 
evaluation.  
Recruitment 
 Data for the EBP project were collected by a retrospective chart reviews. Participants in 
the cardiology practice’s amiodarone clinic were compared to those participants seen by the 
cardiology practice in 2012 on amiodarone. Inclusion criteria included those participants over 18 
years of age newly initiated on amiodarone during the specified time period. Exclusion criteria 
included participants under the age of 18 and those not on amiodarone.  
Data 
 Measures and their reliability and validity. Lack of any previous formal drug 
monitoring program identified the necessity of the evidence-based practice project. Literature 
found in the first three steps of the ACE Star model supported the need for the amiodarone 
clinic to enhance adherence to monitoring guidelines for the use of amiodarone. In the first 
stage of discovery of research, it was recognized that patients on amiodarone therapy have 
adverse effects not recognized in a timely manner and new ways to improve recognition were 
identified through the use of an amiodarone clinic protocol. The second stage of evidence 
summary showed the use of outpatient amiodarone clinics improved the discovery of the 
adverse effects of amiodarone through adherence to monitoring guidelines. Translation to 
Guidelines in the third step utilized HRS guidelines for amiodarone monitoring through the use 
of amiodarone clinics to evaluate patients for early signs of adverse effects of amiodarone 
(Goldschlager et al., 2007).  
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 A data collection tool (see Appendix C) was developed to collect demographic data 
including age, height, weight, gender, and race as well as length of amiodarone use, concurrent 
use of warfarin or digoxin, and a current medication list. This information was used to compare 
the two cohorts during the chart review to assess for bias in the data collected. Statistical 
comparisons were made between the groups in order to increase the reliability that the 
adherence to monitoring results was due to the amiodarone clinic. Consistency of data 
collection was maintained by the use of the same data collection tool for each participant with 
the same person collecting and recording the data. Validity was maintained by the use of data 
measures from the electronic medical record.    
 Collection. A variety of data were collected during this project. A demographic sheet 
was completed by the project manager consisting of the participant’s age, height, weight, 
gender, race, current medical problems, and current medication list. At the bottom of the 
demographic sheet was a flow sheet to record completion of diagnostic testing. This data 
collection sheet was used both for the usual care cohort as well as the amiodarone clinic cohort. 
Data were coded using a code key (see Appendix D) that was secured in a locked cabinet 
separately from the data collection sheets to maintain confidentiality of the participants.  
 Management and analysis. Adherence to guidelines at the initiation of the amiodarone 
clinic was compared to those not enrolled in the amiodarone clinic. The data for those 
participants not enrolled in the amiodarone clinic were obtained from a retrospective chart 
review of the participants on amiodarone in the previous year at the cardiology practice where 
the project took place. Independent t-tests were used to compare age, weight, and height of the 
participants and x2 tests were used to compare adherence to guidelines between the 
participants enrolled in the amiodarone clinic and those not enrolled in the amiodarone clinic as 
well as participant gender, use of warfarin, and use of digoxin. 
 The data collection tool created for use during this EBP project was based on data 
collected in other comparisons of amiodarone clinics included in this EBP project report 
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(Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; 
Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009). The data 
collected were used to compare the two groups included in this EBP project using SPSS 
software.  
Protection of Human Subjects 
 Several methods were employed to protect the participants and their rights during the 
evidence-based practice project. In the early stages of the project, the project manager 
completed training through the National Institute of Health geared towards the protection of 
human subjects. Institutional Review Board approval through Valparaiso University was 
obtained as well as approval through the cardiology practice facility. All data were coded and 
the code key and data were kept separately in a locked cabinet accessible only by the project 
manager.  
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CHAPTER 4 
FINDINGS 
 The purpose of this EBP project was to evaluate if the implementation of a nurse-led 
amiodarone clinic would increase monitoring according to HRS-recommended monitoring 
guidelines. The question was answered using descriptive statistics to analyze data collected 
prior to the implementation of the amiodarone clinic and after through retrospective chart 
reviews.  Statistical and descriptive analyses of the data collected before and after initiation of 
the amiodarone clinic were performed to answer the clinical question. Implications regarding the 
results identified will be discussed at more length in Chapter 5. 
Participant Characteristics 
Data for the baseline cohort were obtained through a retrospective chart review of all 
patients seen in the electrophysiology clinic in the year 2012. A total of ten participants (seven 
males and three females) were identified and included in this baseline cohort. The amiodarone 
clinic was initiated at the cardiology clinic in August of 2013. Nine participants (seven males and 
three females) were identified in the amiodarone clinic cohort for inclusion. Data abstracted from 
the charts included demographic data consisting of age, height, weight, gender, and race, along 
with date of amiodarone initiation, length of amiodarone use, use of warfarin, use of digoxin, 
medical history, and a current medication list. 
 Demographic data (see Tables 4.1 and 4.2) consisting of age, height, weight, race, and 
gender was compared between the two cohorts. An independent samples t test that compared 
the mean height, weight, and age of the two cohorts was conducted (see Table 4.3). No 
significant difference was found between the two groups in age (t(17) = -.03, p = .97), height 
(t(17) = -1.57, p = .13), and weight (t(17) = .82, p = .43). A chi-square test of independence was 
calculated comparing the race and gender between the two groups. No significant difference 
was found for race (X2(1) = 2.01, p = .16) or gender (X2(1) = 3.21, p = .07).  
 
EFFECTS OF AN APN-LED AMIODARONE CLINIC 48 
 
Table 4.1  
Group Statistics for Demographics (age, height, weight) 
 Pre-amio clinic 
(n = 10) 
Post-amio clinic 
(n = 9) 
 M (SD) 
 
Age (in years) 
 
 
  74.50 (10.63) 
 
  74.67 (10.97) 
Height (in inches) 
 
  69.40   (2.41)   71.22   (2.64) 
Weight (in pounds) 
 
215.50 (56.42) 195.22 (51.14) 
 
Table 4.2 
Group Statistics for Demographics (race, gender) 
  Race Gender 
  Caucasian African-American Male Female 
Pre-Amio Clinic 
n (percentage) 
8 (80%) 2 (20%) 7 (70%) 3 (30%) 
Post-Amio Clinic 
n (percentage) 
9 (100%)   0 (0%)      9 (100%)  0 (0%) 
 
Table 4.3 
 
Independent Samples Test for Demographics (age, height, weight) 
 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. 
t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% CI 
Lower Upper 
Age  .05 .84 -.03 17 .97 -.17 4.96 -10.62 10.29 
Height  .06 .81 -1.57 17 .13 -1.82 1.16 -4.27 .62 
Weight  .27 .61 .82 17 .43 20.28 24.81 -32.07 72.62 
 
 
Changes in Outcomes 
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 Prior to the initiation of the amiodarone clinic, it was found that adherence to HRS 
monitoring guidelines needed improvement. All nine participants included in the amiodarone 
cohort completed the educational session. In the pre-amiodarone clinic cohort (n = 10), baseline 
diagnostic monitoring adherence for EKG, TFT, LFT, CXR, and PFT were at 60%, 40%, 30%, 
50%, and 10% respectively (see Table 4.4). After initiation of the amiodarone clinic (n = 9), the 
percentage of adherence increased to 100%, 66.7%, 66.7%, 88.9%, and 33.3% respectively 
(see Table 4.4). Adherence to the baseline eye exam was at 0% for the pre-amiodarone clinic 
cohort and did not change after initiation of the amiodarone clinic. 
Table 4.4 
Adherence to Baseline Monitoring Pre and Post Amiodarone Clinic 
Diagnostics 
Number Completed 
Pre-Amio Clinic Post-Amio Clinic 
(n = 10) (n = 9) 
EKG 6 (60%) 9 (100%) 
TFT 4 (40%) 6 (66.7%) 
LFT 3 (30%) 6 (66.7%) 
CXR 5 (50%) 8 (88.9%) 
PFT 1 (10%) 3 (33.3%) 
Eye Exam 0 0 
 
Statistical testing. Participants in the pre-amiodarone clinic cohort were compared to 
the post-amiodarone clinic cohort with respect to adherence to HRS monitoring guidelines for 
baseline diagnostics (see Table 4.4). When the two groups were compared using the chi-square 
of independence for baseline diagnostics, a significant difference was found in the post-
amiodarone group for baseline EKG (X2 (1) = 4.56, p = .03). Although the results were not 
significantly different, baseline TFT (X2 (1) = 1.35, p = .25), baseline LFT, (X2 (1) = 2.55, p = 
.11), CXR (X2 (1) = 3.32, p = .07), and PFT (X2 (1) = 1.55, p = .21) diagnostics all improved; 
those participants in the post-amiodarone clinic group were more likely to complete the 
recommended diagnostics.   
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Significance. Based on the data collected and analyzed for this EBP project, a nurse-
led amiodarone clinic increased adherence to amiodarone monitoring using HRS guidelines 
(see Figure 4.1). Although not all the results were statistically significant, adherence to 
amiodarone monitoring increased in all diagnostic studies except for eye exams after the 
amiodarone clinic was implemented. Seven (77.8%) of the nine amiodarone clinic participants 
remained on amiodarone during the EBP project.  
Figure 4.1 
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Drug interactions. Out of the nine participants in the amiodarone clinic, six (66.7%) of 
them were concurrently taking warfarin. All six of these patients were followed through a 
Coumadin clinic not part of the amiodarone clinic. Each respective Coumadin clinic was alerted 
to patient initiation of amiodarone and weekly INRs were completed on all six patients for six 
weeks and then weekly until two consecutive INRs were within range per the Coumadin clinic 
protocol. None of the participants in the amiodarone clinic were concurrently taking digoxin.  
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Past medical history. All nine (100%) of the participants in the amiodarone clinic were 
prescribed amiodarone for the treatment of atrial-based arrhythmias. Three (33.3%) of the 
participants had concurrent coronary artery disease. Four (44.4%) of the participants had 
concurrent hyperlipidemia, receiving statin therapy and/or fenofibrate therapy.  
Amiodarone morbidity. Two (22.2%) of the participants in the amiodarone clinic had 
their amiodarone discontinued during this EBP project. One of the patients was admitted for 
pneumonia towards the end of the EBP project which led to the immediate withholding of 
amiodarone until further diagnostics could be completed. A CT scan showed fibrotic changes 
consistent with early amiodarone pulmonary toxicity. The other participant had persistent 
nausea, dizziness, and insomnia after two months on amiodarone. No signs of liver, thyroid, or 
eye effects from amiodarone were observed on either participant during the EBP project.  
Amiodarone mortality. None of the participants died during the EBP project due to 
amiodarone adverse effects or otherwise.  
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CHAPTER 5 
DISCUSSION 
 The purpose of this EBP project was to observe the effects of an APN-led amiodarone 
clinic on adherence to monitoring per HRS guidelines (Goldschlager et al., 2007). Based on 
other research findings in the literature, use of an amiodarone clinic increased adherence to 
monitoring (Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009; 
Spence et al., 2011). This EBP project supported those recommendations as adherence to 
amiodarone monitoring increased after enrollment into the amiodarone clinic. 
Explanation of Findings 
 Data for this project were collected using a retrospective chart review pre and post 
amiodarone clinic. Demographic data were collected from each group and compared for 
significant differences between the two groups which would impact the validity of the findings. 
Baseline monitoring data including baseline EKG, TFT, LFT, CXR, and PFT were collected and 
compared in the pre and post amiodarone participants. Monitoring data were analyzed using 
SPSS software. An independent samples t-test was used to compare age, height, and weight of 
the participants in the pre and post amiodarone clinic participants. Chi-square testing was used 
to evaluate for significant differences in gender and race in the pre and post amiodarone clinic 
participants as well as the appraisal of adherence to diagnostic monitoring between the pre and 
post amiodarone clinic participants.  
Answer to PICOT question. The original PICOT question was: Does enrollment in an 
amiodarone clinic compared with “usual care” change adherence to monitoring as 
recommended by best practice guidelines and allow for earlier recognition of adverse effects of 
amiodarone to decrease negative patient outcomes over a four month time period? Adherence 
to monitoring for baseline EKGs, TFTs, LFTs, CXRs, and PFTs increased over the four month 
period in the APN-led amiodarone clinic. Two patients were found to have significant adverse 
effects from amiodarone prompting discontinuation of amiodarone. Both of these patients 
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recovered after the early recognition of amiodarone adverse effects and discontinuation of 
amiodarone.  
 Pre-amiodarone clinic diagnostic adherence. Of the ten participants identified prior to 
the implementation of the amiodarone clinic, baseline EKG completion was 60%, baseline TFT 
completion was 40%, baseline LFT completion was 30%, baseline CXR completion was 50%, 
and baseline PFT completion was 10%. A review of the literature included studies evaluating 
adherence to baseline amiodarone monitoring in the absence of a dedicated amiodarone clinic 
(Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998; 
Snider et al., 2009; Spence et al., 2011; Stelfox et al., 2004). The EBP project results found in 
the retrospective chart review of participants not enrolled in the amiodarone clinic were similar 
to the results in the literature. Bickford and Spencer (2006) reported higher baseline TFT, LFT, 
CXR, and PFT results (82%, 87%, 87%, and 24% respectively). Stelfox and colleagues (2004) 
reported baseline adherence rates for LFT (42%), TFT (40%), and CXR (50%) which were 
similar to the baseline adherence rates in the pre-amiodarone clinic participants in the EBP 
project.  
Post-amiodarone clinic diagnostic adherence. After implementation of the 
amiodarone clinic, baseline completion of EKG diagnostics rose from 60% to 100% and was 
statistically significant.  When comparing the findings from this EBP project to the literature, 
mixed results were found. In a study by Graham and colleagues (2004), EKG adherence was 
not shown to be significantly improved (41% in the amiodarone clinic cohort as compared to 
32% in the usual care cohort). In other studies, adherence to EKG monitoring in this EBP 
project was similar to those results reported in the literature post implementation of an 
amiodarone clinic (Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 
2009; Spence et al., 2011). Snider and associates (2009) described increased adherence to 
amiodarone monitoring for baseline EKG adherence (from 80% to 100%).  
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Post amiodarone monitoring in this EBP project for TFT (66.7%) and LFT (66.7%) 
increased. In 2004, Graham and colleagues reported improved adherence for continued 
amiodarone monitoring for TFT (66%) and LFT (69%) in the amiodarone clinic cohort as 
compared to the usual care group with adherence rates of 37% for TFT and 38% for LFT. 
Johnson and colleagues (2010) found that baseline adherence rates increased for LFT (from 
44% to 69%) and TFT (from 49% to 55%) after implementation of an amiodarone clinic.  
Spence and associates (2011) found that PFT adherence rates rose from 3.6% to 6.6% 
after implementation of an amiodarone clinic. In this EBP project, similar baseline PFT results 
were document prior to the implementation of the amiodarone clinic (10%), but rose to 33.3% 
after implementation of the amiodarone clinic. Snider and colleagues (2009) reported 
improvement in baseline PFT adherence from 30% to 100% after initiation of an antiarrhythmic 
medications clinic.  
In this EBP project, baseline CXR adherence increased post amiodarone clinic. 
However, in the literature, mixed results for baseline CXR adherence were reported. Snider and 
associates (2009) described increased adherence to amiodarone monitoring for CXR (from 70% 
to 100%) after implementation of antiarrhythmic medications clinic. Spence and colleagues 
(2011) revealed an increase for baseline CXR (from 49.3% to 59.1%) after initiation of an 
amiodarone clinic. Johnson and associates (2010) found that baseline adherence for CXR was 
reported as better in the usual care cohort (56%) as compared to those enrolled in the 
amiodarone clinic (45%).  
The amiodarone clinic for this EBP project did not improve adherence to baseline eye 
exam completion. Only one study included in the literature review discussed baseline 
adherence to eye exams (Graham et al., 2004). In their study, baseline adherence to eye exams 
increased from 15% to 30% after implementation of an amiodarone clinic.  
Post-amiodarone adverse events. Various amiodarone adverse events were 
documented in the literature. In this EBP project, 2 adverse events (22.2%) were documented. 
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One participant had evidence of early pulmonary toxicity and the other participant had 
musculoskeletal and gastrointestinal adverse effects that impacted activities of daily living. 
Adverse events were also reported in the literature. Spence and associates (2011) documented 
liver, thyroid, musculoskeletal, and pulmonary reactions to amiodarone as well as digoxin 
toxicity with concurrent amiodarone administration. When compared with the usual care group, 
the number of patients affected by adverse events was much less (8 reported adverse events in 
the amiodarone clinic group versus 81 in the usual care group). Johnson and researchers 
(2010) described fewer adverse events in the amiodarone clinic cohort (21 as opposed to 48 in 
the usual care cohort) with the top reported adverse event being thyroid-related. Sanoski and 
colleagues (1998) reported adverse effects of amiodarone in 21 (35%) of the 60 patients 
enrolled in the amiodarone clinic with the top reported adverse effect being hypothyroidism. 
Graham and associates (2004) also found similar adverse effects of amiodarone (the most 
common reported were TSH elevation and cough/dyspnea) with more adverse effects 
documented in the amiodarone clinic group.     
Evaluation of the Applicability of the Theoretical and EBP Framework 
Two frameworks led the development, implementation, and analysis of this EBP project: 
King’s Theory of Goal Attainment as the nursing model and the ACE Star Model as the EBP 
framework.  
King’s Theory of Goal Attainment. King’s Theory of Goal Attainment (King, 1971; 
King, 1981) functioned as the theoretical framework for this EBP project. Goal attainment was 
modified to describe the relationship between the project manager and the participants in the 
amiodarone clinic.  
Concepts related to the project manager. In the Theory of Goal Attainment, nursing is 
responsible for assessing patients’ needs to improve health, developing a trusting, therapeutic 
relationship with patients, and guiding patients to achievement of a mutual goal to improve 
health (King, 1971; King, 1981). In this case, it was the project manager’s responsibility to 
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develop a treatment plan with the input of the amiodarone clinic participant. It was important to 
incorporate individualized stressors and barriers to goal attainment as well as deliver the 
education necessary to allow the amiodarone clinic participant to fully take part in the plan of 
care related to goal attainment.   
Concepts related to the participants in the amiodarone clinic. The participants in the 
amiodarone clinic made up the interpersonal system that is the heart of King’s Theory of Goal 
Attainment. The interpersonal system is made up of three parts: the personal system (the 
participant in the amiodarone clinic), the interpersonal system (the interaction between the 
project manager and the participant in the amiodarone clinic), and the social system (those 
individuals whom the participants chose to bring with them to follow-up appointments in the 
amiodarone clinic) (King, 1971; King, 1981). These individuals in the social system included 
family, friends, or caregivers.  
Even though goals were mutually set, the amiodarone clinic participant was still 
responsible for completion of the recommended diagnostic monitoring. It was found after 
discussion with the participants that EKGs were easy to complete due to the fact that they were 
completed at the follow-up appointments with the project manager. Lab diagnostics and CXR 
were also similarly easy to complete as they could be done immediately after the appointments. 
PFTs and eye exams were the most difficult to complete as reported by the amiodarone clinic 
participants as these had to be scheduled at a later date and at another facility. Further 
education could be done stressing the importance of the necessity for baseline PFTs and eye 
exams. This way a more thorough discussion could be had with the patient in order to fully 
attain the mutual goal of completion of all baseline diagnostics upon the initiation of amiodarone.  
Concepts shared by the project manager and the participants in the amiodarone 
clinic. The interactions that took place between the project manager and participants in the 
amiodarone clinic facilitated the mutual attainment of goals; in this case, improved adherence to 
amiodarone monitoring guidelines. These interactions included the initial educational session 
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with the participants. The project manager was sure to discuss any potential barriers to 
adherence of monitoring guidelines and any stressors that might be involved in scheduling the 
diagnostics required outside of the clinic. Barriers and stressors to completion of diagnostic 
testing could include financial complications, transportation complications, or simply lack of 
wanting to have the diagnostics completed. Some stressors were medication specific and 
related to drug-drug interactions between amiodarone and other medications the participants 
were taking. The drug-drug interactions included in this EBP project included warfarin and 
digoxin. None of the participants included in the EBP project were concurrently taking digoxin, 
but six of the nine participants included were taking warfarin. These participants were followed 
in a Coumadin clinic and teaching was done with the staff of the Coumadin clinics. Teaching 
included amiodarone’s interaction with warfarin, the recommended dosage reduction by one-
third to half when starting amiodarone, and weekly INRs for six weeks with dosage adjustments 
necessary to maintain therapeutic ranges, then per routine monitoring (Dulak, 2005; 
Goldschlager et al., 2007; Siddoway, 2003).   
The implementation of the amiodarone clinic was well-received by the cardiology 
practice as well as the amiodarone clinic participants. In fact, the participants in the amiodarone 
clinic shared how pleased they were with the education delivered by the project manager and 
the close follow-up to monitor for adverse effects of amiodarone. 
ACE Star Model. The ACE Star Model yielded a five step process to guide this EBP 
project (Stevens, 2004). The steps include knowledge discovery, evidence summary, 
translation, integration, and evaluation.  
Stage 1: Discovery of research. In this stage, original knowledge is exposed through 
research and scientific inquiry (Stevens, 2004). In this EBP project, several studies were 
identified through a review of literature documenting the success of amiodarone clinics to 
improve adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 2010; Raebel 
et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009). 
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By using discovery of research, knowledge regarding the usefulness of amiodarone clinics in 
adherence to monitoring guidelines was obtained. 
Stage 2: Evidence summary. In this stage, the mass of research is combined into a 
single, significant statement, often in the form of systematic reviews, as well as the recurrent 
update of knowledge with new evidence (Stevens, 2004). Within the current evidence, the use 
of outpatient amiodarone clinics has shown improvement in adherence to monitoring guidelines 
(Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et 
al., 2009; Spence et al., 2011; Tafreshi et al, 2009) and the earlier discovery of adverse effects 
of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009; Tafreshi et al., 
2009). A review of the literature did not reveal an APN-led amiodarone clinic, but other APN-led 
clinics for chronic disease/medication management were successful (Alfakih et al., 2009; Aziz et 
al., 2011; Chandler, 2007; Grange, 2005; Hatchett, 2005; Levine et al., 2012). Success was 
documented by patient-reported symptom relief, facilitation of interdisciplinary referrals, 
improved patient outcomes, fewer hospital readmissions, and better patient education regarding 
chronic condition management (Grange, 2005; Hatchett, 2005; McAfee, 2012). This evidence of 
APN-led clinics for other diseases and medication management were used to support the APN-
led clinic in the EBP project.   
Stage 3: Translation to guidelines. Translation allows for evidence delivery into a 
summary of useful, relevant information into clinical practice guidelines, care standards, clinical 
pathways, organizational protocols, or organizational algorithms through evidence-based 
practices and clinical expertise across many patient populations and settings (Stevens, 2004). 
Many large healthcare organizations (Johnson et al., 2010; Raebel et al., 2006; Snider et al., 
2009; Spence et al, 2011) have instituted outpatient drug monitoring programs to increase 
adherence to monitoring guidelines and increase the identification of adverse drug effects. By 
having a monitoring program dedicated to amiodarone monitoring by HRS guidelines, the 
confusion regarding who was responsible for monitoring these patients was negated and 
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allowed for the early identification of adverse drug effects requiring dose adjustments or 
possibly discontinuation of amiodarone (Goldschlager et al., 2007). Multidisciplinary amiodarone 
clinics as well as pharmacist-led clinics have been documented in the literature. This EBP 
project was the first documented APN-led amiodarone clinic in the literature, and as described, 
the APN-led clinic had the potential to offer additional benefits not found in pharmacist-led 
amiodarone clinics including the ability to order all of the diagnostic testing recommended by 
guidelines including PFTs and CXRs which the pharmacist is not able to do as defined by 
pharmacist scope of practice without a collaborating physician (Johnson et al., 2010; Spence et 
al., 2011). 
Stage 4: Practice integration. Society expects healthcare professionals to remain up-
to-date on current best practices. In order to complete this task, healthcare professionals and 
organizations must be willing to accept new guidelines for practice if the evidence is supportive 
of the change (Stevens, 2004).  
 This EBP project utilized HRS guidelines for the monitoring of amiodarone in a dedicated 
amiodarone clinic (Goldschlager et al., 2007). Baseline monitoring was compared between a 
chart review of patients prior to initiation of an amiodarone clinic in a small northwestern Indiana 
cardiology practice and then another chart review of patients after implementation of an 
amiodarone clinic.   
Stage 5: Evaluation. Evaluation is the final step in the ACE Star Model and consists of 
influences of evidence-based practice on patient outcomes, healthcare professional/patient 
satisfaction, efficacy/efficiency of care, economic analysis, and health status (Stevens, 2004). 
For this EPB project, outcomes evaluated included the number of participants that completed 
baseline diagnostic monitoring before and after initiation of an amiodarone clinic. Previous 
studies and reviews suggested an increase in the adherence to monitoring guidelines with the 
implementation of an amiodarone clinic and the early identification of adverse effects of 
amiodarone allow for early treatment to reduce morbidity and mortality from the use of 
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amiodarone (Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski et al., 
1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009).  
This EBP project demonstrated that the implementation of an APN-led amiodarone clinic 
increased adherence to monitoring guidelines. Furthermore, participants in the amiodarone 
clinic expressed increased satisfaction with the enhanced educational process and more 
frequent office visits to monitor for adverse effects of amiodarone. Two participants in the 
amiodarone clinic were found to have significant enough adverse effects of amiodarone to 
warrant discontinuation of amiodarone therapy, further adding to the usefulness of a dedicated 
amiodarone clinic and potential improved health status. An APN-led clinic would be more cost-
effective than a physician-led amiodarone clinic due to the differences in salary requirements. 
Additionally, an APN-led clinic can overcome some of the ordering difficulties associated with 
the pharmacist-led amiodarone clinics. Pharmacist-led clinics are not able to order certain 
diagnostics such as PFTs, CXRs, and EKGs. 
Strengths and Limitations of the EBP Project 
Strengths. There were several strengths to this EBP project. First, the data collected 
supports the use of a dedicated amiodarone clinic to increase adherence to amiodarone per 
recommended guidelines. This additional data contributes to the current evidence of the 
usefulness of amiodarone clinics in improving adherence to amiodarone monitoring guidelines 
and also adds the new knowledge of an APN-led amiodarone clinic. Second was the utilization 
of APN skills. APNs can provide valuable care through clinical skills that offer symptom relief, 
facilitation of interdisciplinary referrals (McAfee, 2012), as well as provide improved outcomes 
for patients as demonstrated by fewer hospital readmissions (Grange, 2005). These tasks are 
completed by the APN through education of patients regarding their chronic conditions (Grange, 
2005; McAfee, 2012), by more frequent office visits in the amiodarone clinic for earlier 
recognition of adverse effects, and by increased compliance with baseline diagnostic testing. 
Participants with adverse effects requiring treatment from a specialist (such as those 
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experiencing signs and symptoms of hypothyroidism) would be sent to an appropriate 
healthcare provider for treatment. 
One of the ten participants in the usual care cohort required the discontinuation of 
amiodarone due to suspected pulmonary toxicity requiring hospitalization and aggressive 
treatment. Two of the nine participants in the amiodarone cohort required the discontinuation of 
amiodarone due to adverse effects. One of the two participants was hospitalized for pneumonia 
and a CT scan showed fibrotic areas in the lungs suspicious for amiodarone-induced pulmonary 
toxicity. The participant was treated and released after a few days and fully recovered. The 
other participant experienced GI symptoms and muscle tremors which have since resolved 
since stopping amiodarone due to early recognition of adverse effects.  
Naylor and Kurtzman (2010) found that the care provided by APNs was comparable with 
care delivered by physicians and, in some instances, better with regards to patient follow-up; 
patient satisfaction; and more improved screening, assessment, and counseling, qualities which 
provide for a successful amiodarone monitoring clinic. Third, patients in this EBP project 
expressed their satisfaction with the involvement in and individualization of the treatment plan 
as guided by the Theory of Goal Attainment which added to patient accountability for treatment 
compliance.  
Limitations. This EBP project only drew participants in a non-randomized fashion from 
one of the physicians within the cardiology practice over a short period of time. Also, only new 
patients to amiodarone were included in the project. Had the time been extended to one year 
and participants gathered from all four physicians, the number of participants would have been 
larger and more information regarding adherence to amiodarone monitoring per recommended 
guidelines in chronic users of amiodarone could have been compared before and after 
implementation of the amiodarone clinic. Due to the use of electronic medical records, only 
results found in the electronic medical record were included in this EBP project.  
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Improvements to adherence could have been made by using reminder letters if baseline 
diagnostic testing results were not received within one week of amiodarone initiation. Also, an 
alert embedded in the electronic medical record prompting the prescriber of amiodarone to 
assess and order baseline diagnostics as required upon initiation of amiodarone could have 
improved adherence.  
Implications for the Future  
 Practice (APN role or professional nurse). In the state of Indiana, nurse practitioners 
are able to assess patients, order appropriate diagnostic testing, review the diagnostic testing, 
and make recommendations to the treatment plan based on diagnostic testing results. These 
are all skills needed in the implementation of an amiodarone clinic and negate some of the 
limitations found in pharmacist-managed amiodarone clinics. The usefulness of the APN in this 
type of role could be expanded to incorporate a multitude of medications that require diagnostic 
monitoring, leading to a new niche in healthcare for the APN. An example of another APN-led 
clinic may include an arrhythmia clinic dedicated to the monitoring of antiarrhythmic medications 
including amiodarone, sotalol, dofetilide, flecainide, and propafenone. In this role, the APN could 
provide the patient medication education including uses, side effects, adverse effects, 
monitoring protocols; ordering and monitoring of diagnostic testing related to each specific 
antiarrhythmic medication; assessment of adverse effects of the antiarrhythmic medication; 
dose titration as necessary; and referral as needed to other specialty healthcare providers for 
treatment of adverse effects.  
 Theory. King’s Theory of Goal Attainment was a useful theory in the guidance of the 
implementation of the amiodarone clinic due to the incorporation of the patient in the treatment 
plan. Adherence to recommended amiodarone monitoring guidelines was improved through 
goal attainment by leading the EBP project manager and participants through a series of 
transactions to facilitate the decision on a mutual goal while taking into account each 
participant’s unique barriers and stressors to goal attainment. Application of the Theory of Goal 
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Attainment would be suitable in future research requiring common goal attainment between 
researchers and research participants.  
 Research. An APN-led amiodarone clinic research study could not be found in the 
literature. Instead, other APN-led clinics were included in the literature review and applied to 
implementation of an amiodarone clinic. Hospital readmission rates decreased after enrollment 
into a nurse-led asthma clinic (Chandler, 2005); nurse-led heart failure clinics have 
demonstrated an improved quality of life, individualized care, and appropriate medication 
management (Grange, 2005); and nurse-led anticoagulation clinics were more cost effective 
and found that fewer patients in the nurse-led clinic required hospitalization (Aziz et al., 2011). 
This EBP projects starts to fill the knowledge gap found in this area and new research is needed 
regarding effects on amiodarone monitoring adherence, patient outcomes, and cost 
effectiveness of an APN-led amiodarone clinic to continue to fill the knowledge gap discovered. 
Research designs should include longitudinal designs to track the same groups of patients 
before and after enrollment into an APN-led amiodarone clinic while incorporating a cost 
analysis. 
           Education. Further education is necessary regarding the lack of adherence to 
amiodarone monitoring guidelines and the improved adherence to monitoring guidelines through 
the implementation of an amiodarone clinic. This EBP project provides useful information to 
cardiology and primary care nurses regarding lack of adherence to amiodarone monitoring and 
urges those in this specialty area to evaluate current monitoring protocols for adherence rates. 
Future clinics led by APNs might also incorporate other antiarrhythmic medications requiring 
diagnostic monitoring as well as other medications used in the treatment of chronic diseases. 
Not only can this provide another area of expertise for APNs to fulfill, but also improvement of 
patient outcomes through early awareness of drug adverse effects.  
Conclusion 
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The evaluation of this EBP project suggests that implementation of an APN-led 
amiodarone clinic increases adherence to amiodarone monitoring guidelines. A review of the 
literature identified that other amiodarone clinics also improved adherence to amiodarone 
monitoring guidelines, but none were found that were APN-managed. Some of the research 
identified patients who had already suffered amiodarone adverse effects that had gone 
unnoticed by current healthcare providers, giving further indication for a dedicated amiodarone 
clinic. Through patient interactions, patient education, and assessment of barriers and stressors 
to adherence to diagnostic monitoring, improved awareness and early recognition of 
amiodarone adverse effects may be achieved through mutual goal attainment. Patient education 
skills and the ability to monitor health status in a holistic manner are already ingrained into the 
APN role, leading to the opportunity of a new function in healthcare.   
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ACRONYM LIST 
ALT: alanine transaminase 
APN: advanced practice nurse 
AST: aspartate transaminase 
CXR: chest x-ray 
DLCO: diffusing capacity of the lungs for carbon monoxide 
EBP: evidence-based practice 
FT4: free thyroxine 
HRS: Heart Rhythm Society 
INR: international normalized ratio 
LFT: liver function test 
TFT: thyroid function test 
TSH: thyroid stimulating hormone 
PFT: pulmonary function testing 
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Appendix A 
AMIODARONE PATIENT EDUCATION 
Guidelines for Therapy 
 Your doctor has prescribed amiodarone for you. This medicine is used to treat irregular 
heart rhythms. While you are taking this medication, you will need to complete testing before 
you start the medication and every six months while taking the medication. It is preferred that 
you take this medication with food at the same time every day. You should avoid drinking 
grapefruit juice or eating grapefruits. This may decrease the effects of the medication. Please 
report all medications you are taking to your cardiologist as well as any new medications you 
may start. Some medications may react with amiodarone. They may increase or decrease the 
effects. 
Here are the lists of tests that must be completed at the start of your treatment and at certain 
intervals while on amiodarone. Any of these tests may be completed at any time in the future if 
side effects are suspected. 
At Baseline Every 6 Months Yearly 
Liver function test Liver function test Chest x-ray 
Thyroid function test Thyroid function test Eye exam 
Pulmonary function test  EKG 
Chest x-ray   
Eye exam   
EKG   
 
Side Effects 
 Side effects are more likely to occur at higher doses during the loading period. Most side 
effects lessen or go away with a decrease in dose. Amiodarone stays in your body for a long 
period of time. If the medication is stopped, the effects may still remain in your body for several 
weeks or months. Please call your cardiology provider if you experience side effects, which may 
include: 
Shortness of breath/cough Sensitivity to the sun Loss of appetite 
Nausea and vomiting Tiredness/fatigue Constipation 
Skin discoloration Blurry or double vision Muscle weakness/tremors 
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Lung problems 
 In a small number of patients taking amiodarone over a long period of time, lung damage 
can occur. This damage can be lessened or reversed completely if amiodarone is stopped early. 
If you develop shortness of breath or a cough, please tell your cardiology provider immediately.  
Skin reactions 
 Your skin may develop a redder look. This may increase when exposed to sunlight. A 
bluish-gray discoloration may also be seen. These reactions are normal side effects. 
Sunscreen, hats, and long-sleeves/pants are recommended to help decrease these effects. 
Eye problems 
 Amiodarone can sometimes deposit small particles in the eye. Sometimes blurry or 
double vision can occur. These deposits can be seen on a thorough eye exam by an 
ophthalmologist (eye doctor). If eye deposits are seen on exam and are causing vision loss, the 
amiodarone dose may have to be decreased or stopped completely. 
Sleep Disturbances 
 While taking amiodarone, you may experience changes in sleep patterns. Insomnia is 
common, especially during the loading period. This will lessen as the dose is reduced. If 
insomnia is a problem, please discuss this with your cardiology provider for treatment options. 
 
As with any medication, your doctor will determine if the benefits of amiodarone 
outweigh the risks or complications due to side effects. If you experience side effects, 
please contact your cardiology provider. A dose adjustment or further testing may be 
needed. 
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Appendix B 
Amiodarone Clinic Patient Evaluation Protocol 
I. At the initial visit: 
A. Basic history and physical 
1. Vital signs: BP, HR 
2. Lung exam 
3. Heart exam 
4. Review of current medication list to check for potential drug 
interactions with amiodarone 
B. Baseline tests if not obtained at cardiology consultation 
1. CXR 
2. EKG 
3. Pulmonary function test 
4. Ophthalmology exam 
5. CMP, Magnesium, TFT (and PT/INR and/or digoxin level if 
appropriate) 
C. Patient education on amiodarone use, side effects, interventions to decrease 
side effects 
II. At the one month visit: 
A. Basic history and physical to elicit for adverse effects 
1. Fatigue 
2. Cough/shortness of breath 
3. Palpitations 
4. Syncope 
5. Blurry/double vision or loss of vision 
6. Skin changes 
7. Weight loss/nausea/vomiting 
8. Muscle weakness/tremors 
9. Sleep disturbances 
10. Changes in medications 
B. Discuss baseline testing 
C. Order further testing based on baseline testing results or patient complaints of 
side effects 
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Appendix C 
Code # ________ 
Amiodarone Clinic Data Collection Tool 
Patient Age: __________ Patient Height: __________ Patient Weight: __________  
New to Amiodarone? __________ If no, length of amiodarone use: __________ 
Date of Initiation: __________ Warfarin? __________ Digoxin? __________ 
Past Medical History: 
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________ 
Current Medications: 
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________ 
 
 
 Baseline 
Week 
1 
Week 
2 
Week 
3 
Week 
4 
Week 
5 
Week 
6 
3 
Month 
6 
Month 
1 
Year 
 
H & P         
  
 
EKG         
  
 
TFT         
  
 
LFT         
  
 
CXR         
  
 
PFT         
  
Eye 
Exam         
  
Digoxin 
Level         
  
 
INR         
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*shaded boxes indicate when diagnostic study is needed (3 month testing optional) 
*place date of exam in box 
Recheck as Needed for Symptomatic Adverse Drug Reactions 
 
EKG 
        
 
TFT 
        
 
LFT 
        
 
CXR 
        
 
PFT 
        
Eye 
Exam 
        
Digoxin 
Level 
        
 
INR 
        
*place date of exam in box 
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Appendix D 
Amiodarone Clinic Code Key 
Code Number Patient Name Date of Birth Medical Record # 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
